Phreesia (PHR) 10-K 31 Mar 22 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jan. 31, 2022	Mar. 25, 2022	Jul. 31, 2021
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001412408
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 31, 2022
Current Fiscal Year End Date	--01-31
Document Transition Report	false
Entity File Number	001-38977
Entity Registrant Name	PHREESIA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2275479
Entity Address, Address Line One	434 Fayetteville St
Entity Address, Address Line Two	Suite 1400
Entity Address, City or Town	Raleigh
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27601
City Area Code	888
Local Phone Number	654-7473
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	PHR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 3,560,759,139
Entity Common Stock, Shares Outstanding (in shares)		51,946,395
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.

Audit Information

Audit Information	12 Months Ended
	Jan. 31, 2022
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	Philadelphia, PA
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Current:
Cash and cash equivalents	$ 313,812	$ 218,781
Settlement assets	19,590	15,488
Accounts receivable, net of allowance for doubtful accounts of $863 and $699 as of January 31, 2022 and 2021, respectively	40,262	29,052
Deferred contract acquisition costs	1,642	1,693
Prepaid expenses and other current assets	11,043	7,254
Total current assets	386,349	272,268
Property and equipment, net of accumulated depreciation and amortization of $53,321 and $40,148 as of January 31, 2022 and 2021, respectively	34,645	26,660
Capitalized internal-use software, net of accumulated amortization of $31,139 and $25,476 as of January 31, 2022 and 2021, respectively	17,643	10,476
Operating lease right-of-use assets	2,337	2,654
Deferred contract acquisition costs	2,437	1,248
Intangible assets, net of accumulated amortization of $1,178 and $525 as of January 31, 2022 and 2021, respectively	12,772	2,725
Deferred tax asset	515	658
Goodwill	33,621	8,307
Other assets	4,157	1,670
Total Assets	494,476	326,666
Current:
Settlement obligations	19,590	15,488
Current portion of finance lease liabilities and other debt	5,821	4,864
Current portion of operating lease liabilities	1,281	1,087
Accounts payable	5,119	4,389
Accrued expenses	20,128	18,324
Deferred revenue	16,493	10,838
Total current liabilities	68,432	54,990
Long-term finance lease liabilities and other debt	7,423	6,471
Operating lease liabilities, non-current	1,276	1,899
Long-term deferred revenue	65	0
Total liabilities	77,196	63,360
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Common stock, $0.01 par value—500,000,000 shares authorized as of January 31, 2022 and 2021, respectively; 52,095,964 and 44,880,883 shares issued as of January 31, 2022 and 2021, respectively	521	449
Additional paid-in capital	860,657	579,599
Accumulated deficit	(429,938)	(311,777)
Treasury stock, at cost, 301,003 and 99,520 shares as of January 31, 2022 and 2021, respectively	(13,960)	(4,965)
Total Stockholders’ Equity	417,280	263,306
Total Liabilities and Stockholders’ Equity	$ 494,476	$ 326,666

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 863	$ 699
Accumulated depreciation and amortization, property and equipment	53,321	40,148
Accumulated amortization of capitalized internal-use software	31,139	25,476
Accumulated amortization of intangible assets	$ 1,178	$ 525
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	52,095,964	44,880,883
Treasury stock (in shares)	301,003	99,520

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Revenue:
Total revenue	$ 213,233	$ 148,677	$ 124,784
Expenses:
Cost of revenue (excluding depreciation and amortization)	42,669	23,461	16,831
Payment processing expense	38,719	28,925	27,889
Sales and marketing	106,421	42,972	32,357
Research and development	52,265	22,622	18,623
General and administrative	68,674	40,460	30,458
Depreciation	14,985	9,770	8,753
Amortization	6,317	6,138	5,171
Total expenses	330,050	174,348	140,082
Operating loss	(116,817)	(25,671)	(15,298)
Other (expense) income, net	(78)	1	(1,023)
Change in fair value of warrant liability	0	0	(3,307)
Interest (expense) income, net	(1,084)	(1,573)	(2,445)
Total other expense, net	(1,162)	(1,572)	(6,775)
Loss before (provision for) benefit from income taxes	(117,979)	(27,243)	(22,073)
(Provision for) benefit from income taxes	(182)	(49)	1,780
Net loss	(118,161)	(27,292)	(20,293)
Preferred stock dividends paid	0	0	(14,955)
Accretion of redeemable preferred stock	0	0	(56,175)
Net loss attributable to common stockholders, basic	(118,161)	(27,292)	(91,423)
Net loss attributable to common stockholders, diluted	$ (118,161)	$ (27,292)	$ (91,423)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (2.37)	$ (0.69)	$ (4.50)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (2.37)	$ (0.69)	$ (4.50)
Weighted-average common shares outstanding - basic (in shares)	49,888,436	39,519,640	20,301,189
Weighted-average common shares outstanding - diluted (in shares)	49,888,436	39,519,640	20,301,189
Subscription and related services
Revenue:
Total revenue	$ 95,514	$ 69,042	$ 56,357
Payment processing fees
Revenue:
Total revenue	65,201	49,900	46,500
Life sciences
Revenue:
Total revenue	$ 52,518	$ 29,735	$ 21,927

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated deficit	Treasury stock
Beginning balance, stockholders' equity (in shares) at Jan. 31, 2019		1,994,721
Beginning balance, stockholders' equity (deficit) at Jan. 31, 2019	$ (210,974)	$ 20	$ 0	$ (210,994)	$ 0
Stockholders’ equity
Net loss	(20,293)			(20,293)
Stock-based compensation expense	$ 6,177		6,177
Exercise of stock options and vesting of restricted stock units (in shares)	691,371	734,382
Exercise of stock options and vesting of restricted stock units	$ 1,809	$ 7	1,802
Issuance of common stock warrants	833		833
Accretion of redeemable preferred stock (See Note 7)	(56,175)		(2,977)	(53,198)
Payment of preferred stock dividends (See Note 7)	(14,955)		(14,955)
Issuance of common stock, net of issuance costs (in shares)		7,812,500
Issuance of common stock, net of issuance costs	124,370	$ 78	124,292
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		25,311,535
Conversion of preferred stock into common stock (See Note 7)	262,665	$ 253	262,412
Cashless exercise of common stock warrants (in shares)		168,862
Cashless exercise of common stock warrants	2	$ 2
Conversion and exercise of preferred stock warrants into common stock (in shares)		588,763
Conversion and exercise of preferred stock warrants into common stock (See Note 7)	8,805	$ 6	8,799
Treasury stock from vesting of restricted stock units	(399)				(399)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2020		36,610,763
Ending balance, stockholders' equity (deficit) at Jan. 31, 2020	101,865	$ 366	386,383	(284,485)	(399)
Stockholders’ equity
Net loss	(27,292)			(27,292)
Stock-based compensation expense	$ 13,489		13,489
Exercise of stock options and vesting of restricted stock units (in shares)	2,216,368	2,459,782
Exercise of stock options and vesting of restricted stock units	$ 5,300	$ 25	5,275
Issuance of common stock, net of issuance costs (in shares)		5,750,000
Issuance of common stock, net of issuance costs	174,510	$ 57	174,453
Cashless exercise of common stock warrants (in shares)		60,338
Cashless exercise of common stock warrants	0	$ 1	(1)
Treasury stock from vesting of restricted stock units	(4,566)				(4,566)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2021		44,880,883
Ending balance, stockholders' equity (deficit) at Jan. 31, 2021	263,306	$ 449	579,599	(311,777)	(4,965)
Stockholders’ equity
Net loss	(118,161)			(118,161)
Stock-based compensation expense	$ 29,668		29,668
Exercise of stock options and vesting of restricted stock units (in shares)	1,439,186	1,997,551
Exercise of stock options and vesting of restricted stock units	$ 4,143	$ 20	4,123
Issuance of common stock for employee stock purchase plan (in shares)	42,530	42,530
Issuance of common stock for employee stock purchase plan	$ 1,506		1,506
Issuance of common stock, net of issuance costs (in shares)		5,175,000
Issuance of common stock, net of issuance costs	245,813	$ 52	245,761
Treasury stock from vesting of restricted stock units	(8,995)				(8,995)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2022		52,095,964
Ending balance, stockholders' equity (deficit) at Jan. 31, 2022	$ 417,280	$ 521	$ 860,657	$ (429,938)	$ (13,960)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 290	$ 6,412

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Operating activities:
Net loss	$ (118,161)	$ (27,292)	$ (20,293)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	21,302	15,908	13,924
Non-cash stock-based compensation expense	36,144	13,489	6,177
Change in fair value of warrants liability	0	0	3,307
Amortization of deferred financing costs and debt discount	288	389	445
Loss on extinguishment of debt	0	0	1,073
Cost of Phreesia hardware purchased by customers	672	762	741
Deferred contract acquisition costs amortization	2,211	2,025	1,977
Non-cash operating lease expense	1,004	1,766	0
Change in fair value of contingent consideration liabilities	258	0	0
Deferred tax asset	143	(65)	(775)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(10,216)	(6,619)	(5,905)
Prepaid expenses and other assets	(7,192)	(1,600)	(312)
Deferred contract acquisition costs	(3,349)	(1,652)	(2,097)
Accounts payable	2,881	(3,821)	(30)
Accrued expenses and other liabilities	(2,983)	6,004	3,681
Lease liability	(1,060)	(1,786)	0
Deferred revenue	3,348	5,382	(1,087)
Net cash (used in) provided by operating activities	(74,710)	2,890	826
Investing activities:
Acquisitions, net of cash acquired	(34,423)	(6,510)	0
Capitalized internal-use software	(12,385)	(7,334)	(5,305)
Purchases of property and equipment	(18,420)	(11,241)	(7,015)
Net cash used in investing activities	(65,228)	(25,085)	(12,320)
Financing activities:
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions	245,813	174,800	130,781
Payment of preferred stock dividends	0	0	(14,955)
Proceeds from issuance of common stock upon exercise of stock options	4,889	4,385	1,809
Treasury stock to satisfy tax withholdings on stock compensation awards	(8,995)	(4,965)	0
Payment of offering costs	0	(290)	(6,217)
Proceeds from employee stock purchase plan	1,979	0	0
Insurance financing agreement	0	2,009	0
Finance lease payments	(4,267)	(2,630)	(1,898)
Principal payments on financing agreements	(1,039)	(1,691)	0
Debt issuance costs	0	(69)	(112)
Loan facility fee payment	(125)	(225)	0
Financing payments of acquisition-related liabilities	(3,286)	0	0
Proceeds from revolving line of credit	0	0	9,876
Payments of revolving line of credit	0	(20,663)	(17,676)
Proceeds from term loan	0	0	20,000
Repayment of term loan and loan payable	0	0	(21,042)
Debt extinguishment costs	0	0	(300)
Net cash provided by financing activities	234,969	150,661	100,266
Net increase in cash and cash equivalents	95,031	128,466	88,772
Cash and cash equivalents—beginning of year	218,781	90,315	1,543
Cash and cash equivalents—end of year	313,812	218,781	90,315
Supplemental information of non-cash investing and financing information:
Right-of-use assets recorded in exchange for operating lease liabilities	81	4,359	0
Property and equipment acquisitions through finance leases	7,394	8,885	2,047
Capitalized software acquired through vendor financing	0	174	0
Purchase of property and equipment and capitalized software included in accounts payable	1,124	3,359	1,253
Cashless transfer of term loan and related accrued fees into increase in debt balance	0	20,257	0
Cashless transfer of lender fees through increase in debt balance	0	406	0
Issuance of warrants related to debt	0	0	833
Receivables for cash in-transit on stock option exercises	169	915	0
Cashless exercise of common stock warrants	0	3,060	3,530
Capitalized stock based compensation	489	0	0
Cash paid for:
Interest	802	1,465	2,310
Income taxes	$ 49	$ 64	$ 0

Background and liquidity

Background and liquidity	12 Months Ended
	Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	Background and liquidity (a) Background Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through the SaaS-based technology platform (the "Phreesia Platform" or "Platform"), the Company offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments and clinical support. The Company’s Platform also provides life sciences companies, patient advocacy, public interest and other not-for-profit organizations with a channel for targeted and direct communication with patients. In connection with the patient intake and registration process, Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005, and has several offices in the U.S. and Canada. The Company completed an initial public offering ("IPO") in July 2019. During fiscal 2021, the Company changed its headquarters from New York, New York to Raleigh, North Carolina. b) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year. Management believes that the Company’s cash and cash equivalents at January 31, 2022, along with cash generated in the normal course of business, and available borrowing capacity under its Second Amended and Restated Loan and Security Agreement (the "Second SVB Facility") with Silicon Valley Bank ("SVB") (Note 6), are sufficient to fund its operations for at least the next 12 months. On March 28, 2022, the Company entered into the First Loan Modification Agreement to the Second SVB Facility (as amended, the "Third SVB Facility"), to increase the available borrowing capacity to $100.0 million from $50.0 million.

Basis of presentation

Basis of presentation	12 Months Ended
	Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation (a) Consolidated Financial Statements The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company"). (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2022, 2021 and 2020, refer to the fiscal years ended January 31, 2022, 2021 and 2020, respectively.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies(a) Use of estimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets. (b) Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers , as well as for additional details about the Company's products and service lines. (c) Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2022 and January 31, 2021. As of January 31, 2022, the Company had receivables from one entity that accounted for at least 10% of total accounts receivable. (d) Risks and uncertainties Risks Related to the COVID-19 Pandemic In March 2020, the World Health Organization declared the ongoing outbreak of a novel strain of coronavirus ("COVID-19") a pandemic. There continues to be uncertainty as to the duration and extent to which the global COVID-19 pandemic, as well as the emergence of new variants, may adversely impact the Company's business operations, financial performance, and results of operations, as well as macroeconomic conditions, at this time. Other Risks and Uncertainties The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third party vendors, partners, and service providers. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of our business and our customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of our operations, adversely impacting the Company’s operating results and our ability to meet our obligations and commitments. See Note 6 - Finance leases and other debt, for a summary of our contractual commitments as of January 31, 2022. (e) Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation. (f) Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways. (g) Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $4,007, $558 and $251 for the fiscal years ended 2022, 2021 and 2020, respectively. (h) Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period. (i) General and administrative General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead. (j) Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements. (k) Amortization Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets. (l) Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market account meets the definition of cash equivalents. (m) Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two (n) Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor. (o) Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2022 and 2021, the Company has reserved $863 and $699, respectively, for the allowance for doubtful accounts. Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5). (p) Property and equipment Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations. (q) Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three (r) Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations. When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations. (s) Goodwill and intangible assets Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount. All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. (t) Long-lived assets Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented. (u) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes. (v) Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements. (w) Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718 , Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield. See Note 8 - Equity Based Compensation, for additional information on stock-based compensation. (x) Fair value of financial instruments Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. (y) Equity offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations. (z) Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net. (aa) New accounting pronouncements Impact of recently adopted accounting pronouncements In October 2021, the FASB issued ASU No. 2021-08, Business Combinations - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update creates an exception to the recognition and measurement principles in ASC 805, Business Combinations. The amendments require an acquirer to recognize and measure contracts assets and liabilities related to customer contracts acquired in a business combination under the guidance in ASC 606, Revenue from Contracts with Customers, rather than using fair value. The Company adopted the new guidance for the fiscal year ended January 31, 2022 and applied the new guidance to the acquisition of Insignia Health, LLC, ("Insignia") which occurred during the year ended January 31, 2022. For the acquisition of Insignia, the Company recognized and measured acquired deferred revenue in accordance with ASC 606. The Company measured acquired deferred revenue as if the Company had originated the related acquired customer contracts. In accordance with practical expedients available in ASU 2021-08, the Company reflected in acquired deferred revenue the aggregate effect of all contract modifications that occurred prior to the acquisition date, and the Company determined the standalone selling price of each performance obligation included in acquired deferred revenue as of the acquisition date. The effect of applying the practical expedients was not significant. See Note 16 - Acquisitions for additional information regarding the acquisition of Insignia. On February 1, 2020, the Company adopted ASU No. 2016-02, Leases (Topic 842) which requires lessees to record most leases on their balance sheets but to recognize the expenses in their statement of operations in a manner similar to the prior standard. Topic 842 states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The Company adopted the new lease guidance using a modified retrospective transition method applied to those leases which were not completed as of February 1, 2020. As a result, the Company was not required to adjust its comparative period financial information for effects of the standard or make the new required lease disclosures for the periods before the date of adoption. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all of its leases. This means, for those leases that qualify, the Company will not recognize right-of-use assets or lease liabilities, including existing short-term leases as of the transition date. The Company also elected the practical expedient to not separate lease and non-lease components for its office and computer equipment leases. Upon adoption of Topic 842 the Company recognized operating lease right-of-use assets and operating lease liabilities related to its office leases of $2,741 and $2,928, respectively. The Company’s accounting for lessee finance and all lessor leases remains substantially unchanged from legacy guidance. The standard did not have a significant impact on the Company's statements of operations or statements of cash flows. No adjustment to accumulated deficit was recorded because the adoption did not change the Company's net assets. Recent accounting pronouncements not yet adopted There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.

Composition of certain financia

Composition of certain financial statement captions	12 Months Ended
	Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]
Composition of certain financial statement captions	Composition of certain financial statement captions (a) Accrued expenses Accrued expenses at January 31, 2022 and 2021 are as follows: January 31, 2022 2021 Payroll-related expenses and taxes $ 10,780 $ 8,946 Payment processing fees liability 3,502 2,853 Acquisition-related liabilities 96 3,386 Tax liabilities 2,093 700 Other 3,657 2,439 Total $ 20,128 $ 18,324 Accrued expenses for payroll-related expenses and taxes include approximately $7.5 million of liabilities expected to be settled in shares. See Note 8 - Equity-based compensation for additional information. (b) Property and equipment Property and equipment at January 31, 2022 and 2021 are as follows: Useful life January 31, 2022 2021 PhreesiaPads and Arrivals Kiosks 3 $ 26,387 $ 25,837 Computer equipment 3 53,957 33,558 Computer software 3 to 5 5,311 5,105 Hardware development 3 1,024 1,024 Furniture and fixtures 7 539 539 Leasehold improvements 2 748 745 Total property and equipment $ 87,966 $ 66,808 Less accumulated depreciation (53,321) (40,148) Property and equipment — net $ 34,645 $ 26,660 Depreciation expense related to property and equipment amounted to $14,985, $9,770 and $8,753 for the fiscal years ended January 31, 2022, 2021 and 2020, respectively. Assets acquired under finance leases included in computer equipment were $27,310 and $19,933 at January 31, 2022 and 2021, respectively. Accumulated amortization of assets under finance lease was $15,025 and $10,389 at January 31, 2022 and 2021, respectively. (c) Capitalized internal-use software For the fiscal years ended January 31, 2022, 2021 and 2020, the Company capitalized $12,830, $7,663 and $5,852 of costs related to the Phreesia Platform, respectively. During the fiscal years ended January 31, 2022, 2021 and 2020 amortization expense of capitalized internal-use software was $5,664, $5,884 and $4,933, respectively. (d) Intangible assets and goodwill The following presents the details of intangible assets as of January 31, 2022 and January 31, 2021. Useful Life January 31, (years) 2022 2021 Acquired technology 5 $ 1,410 $ 1,410 Customer relationship 7 to 10 6,340 1,840 License 15 6,200 — Total intangible assets, gross carrying value $ 13,950 $ 3,250 Less accumulated amortization (1,178) (525) Net carrying value $ 12,772 $ 2,725 Amortization expense associated with intangible assets for the fiscal years ended January 31, 2022, 2021 and 2020 was $653, $254 and $238, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2022: January 31, 2022 2023 $ 1,371 2024 1,358 2025 1,273 2026 1,242 2027-Thereafter 7,528 Total $ 12,772 The following table presents a roll-forward of goodwill for the years ended January 31, 2020, 2021 and 2022: Balance at January 31, 2020 $ 250 Goodwill acquired during the year ended January 31, 2021 8,057 Balance at January 31, 2021 8,307 Goodwill acquired during the year ended January 31, 2022 25,314 Balance at January 31, 2022 $ 33,621 The Company did not record any impairments of goodwill during the years ended January 31, 2022, 2021 or 2020. Additions to goodwill during the year ended January 31, 2022 are net of a $96 measurement period adjustment for the QueueDr acquisition. (e) Accounts receivable Accounts Receivable as of January 31, 2022 and 2021 are as follows: January 31, 2022 2021 Billed $ 40,733 $ 28,464 Unbilled 392 1,287 Total accounts receivable, gross 41,125 29,751 Less accounts receivable allowances (863) (699) Total accounts receivable $ 40,262 $ 29,052 Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2021 and 2022: Balance, January 31, 2020 $ 943 Bad debt expense 454 Write-offs and adjustments (698) Balance, January 31, 2021 699 Bad debt expense 212 Write-offs and adjustments (48) Balance, January 31, 2022 $ 863 The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible. (f) Prepaid and other current assets Prepaid and other current assets as of January 31, 2022 and 2021 are as follows: January 31, 2022 2021 Prepaid software and business systems $ 3,738 $ 2,322 Prepaid PhreesiaPads — 18 Prepaid data center expenses 3,230 1,211 Prepaid insurance 1,924 1,311 Other prepaid expenses and other current assets 2,151 2,392 Total prepaid and other current assets $ 11,043 $ 7,254 (g) Cloud computing implementation costs

Revenue and Contract Costs

Revenue and Contract Costs	12 Months Ended
	Jan. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue and Contract Costs	Revenue and Contract Costs The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Phreesia Platform, payment processing fees based on patient payment volume, and fees from life sciences companies to deliver marketing content to its patients using the Phreesia Platform. The Company accounts for revenue from contracts with customers by applying the requirements of ASC 606. Accordingly, the Company determines revenue recognition through the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services. The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type. (a) Subscription and related services In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other applications. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. The Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 842, Leases . The amount of subscription and related services revenues recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $6,489, $6,312 and $5,985 for the years ended January 31, 2022, 2021 and 2020, respectively. In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from Phreesia’s Platform and are therefore recognized over the term of the contract. Revenue from sales of Phreesia hardware and training are recognized in the period they are delivered to clients. (b) Payment processing fees The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions. The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees. The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers. The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company. As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations. (c) Life sciences The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to targeted patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered. (d) Disaggregation of revenue Revenue from the Company’s contracts with its customers are disaggregated by revenue source on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees and digital marketing solutions sold to life sciences companies. In addition, substantially all of the Company’s revenue is derived from customers in the United States. (e) Remaining performance obligations The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue). (f) Contract balances Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying balance sheets. The following table represents a roll-forward of contract assets: January 31, 2022 2021 Beginning Balance $ 1,287 $ 676 Amount transferred to receivables from beginning balance of contract assets (1,287) (676) Increases in contract assets due to acquisitions 243 — Contract asset additions, net of reclassification to receivables 149 1,287 Ending Balance $ 392 $ 1,287 The following table represents a roll-forward of deferred revenue: January 31, 2022 2021 Beginning Balance $ 10,838 $ 5,401 Revenue recognized that was included in deferred revenue at the beginning of the period (10,838) (5,097) Revenue recognized that was not included in deferred revenue at the beginning of the period (18,334) (1,512) Increases in deferred revenue due to acquisitions 2,372 55 Increases due to invoicing prior to satisfaction of performance obligations 32,520 11,991 Ending Balance $ 16,558 $ 10,838 (g) Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three The following table represents a roll-forward of deferred contract acquisition costs: January 31, 2022 2021 Beginning balance $ 2,941 $ 3,314 Additions to deferred contract acquisition costs 3,349 1,652 Amortization of deferred contract acquisition costs (2,211) (2,025) Ending balance 4,079 2,941 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,642 1,693 Deferred contract acquisition costs, non-current 2,437 1,248 Total deferred contract acquisition costs $ 4,079 $ 2,941

Finance leases and other debt

Finance leases and other debt	12 Months Ended
	Jan. 31, 2022
Debt Disclosure [Abstract]
Finance leases and other debt	Finance leases and other debt As of January 31, 2022 and 2021, the Company had the following outstanding finance leases and other debt balances: January 31, 2022 2021 Finance leases $ 12,884 $ 9,702 Financing arrangements 266 1,533 Accrued interest and payments 94 100 Total finance lease liabilities and other debt $ 13,244 $ 11,335 Less - current portion of finance lease liabilities and other debt (5,821) (4,864) Long-term finance leases and other debt $ 7,423 $ 6,471 (a) Financing arrangements On November 2, 2018, the Company entered into a vendor financing agreement with a principal amount of $1,256 to finance the acquisition of certain internal use software licenses. As of January 31, 2022 and 2021, the outstanding principal balance of the financing agreement was $175 and $504, respectively. Interest accrues at an annual rate of 9.83%. The Company is required to repay $183 for the financing arrangement in June 2022, which includes principal and interest. On April 10, 2020, the Company entered into a vendor financing agreement with a principal amount of $174 to finance the acquisition of certain internal use software licenses. As of January 31, 2022 and 2021, the outstanding principal balance of the financing agreement was $90 and $133, respectively. Interest accrues at an annual rate of 2.94%. The Company is required to make equal annual payments of $46 in May 2022 and May 2023, which includes principal and interest. On July 21, 2020, the Company entered into an insurance premium financing agreement in order to finance its premium payments for directors' and officers' insurance. As of January 31, 2022 and 2021, there was no outstanding principal amount and $673 in outstanding principal under the agreement, respectively. The agreement bears interest of 2.6% per annum. The balance of the financing agreement was paid off during the first quarter of fiscal 2022, and there was no balance outstanding as of January 31, 2022. (b) Finance leases See Note 10 - Leases for more information regarding finance leases. On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. In connection with the transaction, the Company recorded a $1,073 loss on extinguishment of debt within other (expense) income, net for the settlement of previously outstanding loans payable. On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility. The Second SVB Facility modified the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. The borrowing capacity could be increased to $65,000 at the sole discretion of Silicon Valley Bank. Upon entering into the Second SVB Facility, the Company borrowed $20,663 against the revolving credit facility and used the proceeds to repay all amounts due under the First SVB Facility term loan. Borrowings under the Second SVB Facility were payable on May 5, 2025. Borrowings under the Second SVB Facility bore interest, which was payable monthly, at a floating rate equal to the greater of the Wall Street Journal Prime Rate or 4.5%. The interest rate would decrease by 0.5% upon reaching a defined level of Adjusted EBITDA as defined in the Second SVB Facility. For the year ended January 31, 2022, the interest rate on the Second SVB Facility was 4.5%. In addition to principal and interest due under the revolving credit facility, the Company was required to pay an annual commitment fee of $125 per year. The Second SVB Facility was paid off in December 2020. The Company had $50,000 of availability as of January 31, 2022. During the year ended January 31, 2021, the Company accounted for the settlement of the First SVB Facility term loan and the borrowings under the Second SVB Facility as a modification of debt and deferred $531 of fees including $406 of fees to terminate the First SVB Facility and $125 of fees to enter into the Second SVB Facility. Maturities of finance leases and other debt in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt Fiscal year ending January 31: 2023 $ 5,821 $ 5,600 $ 221 2024 4,866 4,727 139 2025 2,401 2,401 — 2026 156 156 — 2027 — — — Total maturities of finance leases and other debt $ 13,244 $ 12,884 $ 360 The following table presents the components of interest (expense) income, net: Fiscal years ended January 31, 2022 2021 2020 Interest expense (1) $ (1,163) $ (1,695) $ (3,043) Interest income 79 122 598 Interest (expense) income, net $ (1,084) $ (1,573) $ (2,445) (1) Includes amortization of deferred financing costs and original issue discount

Stockholders' Equity and Prefer

Stockholders' Equity and Preferred Stock	12 Months Ended
	Jan. 31, 2022
Equity [Abstract]
Stockholders' Equity and Preferred Stock	Stockholders' Equity and Preferred Stock (a) Common stock The Company closed an IPO on July 22, 2019 and filed an amended and restated certification of incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. In connection with the IPO, the Company issued and sold 7,812,500 shares of common stock at a public offering price of $18.00 per share, resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions of $9,844 but before deducting deferred offering costs of $6,412. In addition to the shares of common stock sold by the Company upon the IPO, certain selling stockholders sold an aggregate 2,868,923 shares of common stock as part of the IPO, and 588,763 shares of common stock were issued upon the cashless exercise of common stock warrants. On October 23, 2020, the Company completed a follow-on offering of its common stock. In connection with the follow-on offering, the Company issued and sold 5,750,000 shares of common stock at an issuance price of $32.00 per share resulting in net proceeds of $174,800, after deducting underwriting discounts and commissions. The Company also incurred $290 of net third party offering costs. On April 12, 2021, the Company completed a follow-on offering of its common stock. In connection with this offering, the Company issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share resulting in net proceeds of $245,813, after deducting underwriting discounts and commissions. (b) Treasury stock The Company's equity based compensation plan allows for the grant of non-vested stock options, RSUs and TSR PSUs to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Under the provision of the plans, for RSU and PSU awards, unless otherwise elected, participants fulfill their related income tax withholding obligation by having shares withheld at the time of vesting. On the date of vesting of the RSU or PSU, the Company divides the participant's income tax obligation in dollars by the closing price of its common stock and withholds the resulting number of vested shares. The shares withheld are then transferred to the Company's treasury stock at cost. (c) Preferred Stock Upon closing of the IPO, the Company's outstanding shares of Senior A redeemable convertible preferred stock ("Senior A Preferred"), Senior B redeemable convertible preferred stock ("Senior B Preferred", and together with the Senior A Preferred, the "Senior Preferred"), and the Junior convertible preferred stock (the "Junior Preferred", and together with the Senior Preferred, the "Convertible Preferred") automatically converted into shares of common stock and all outstanding shares of the Company's redeemable preferred stock ("Redeemable Preferred") were automatically extinguished and cancelled at the closing of the IPO. In addition, the Company's warrants to purchase shares of Senior Preferred were converted into warrants to purchase shares of the Company's common stock upon the closing of the IPO. Also, in connection with the IPO, the Company paid $14,955 in dividends to the Senior Preferred stockholders. The following table summarizes changes in the Company's Series A Convertible Preferred and Redeemable Preferred for the fiscal year ended January 31, 2020: Redeemable preferred stock Senior A Senior B Junior Redeemable Shares Amount Shares Amount Shares Amount Shares Amounts Total Balance, January 31, 2019 13,674,365 $ 79,311 9,197,142 $ 51,872 32,746,041 $ 32,746 42,560,530 $ 42,561 $ 206,490 Accretion of redeemable preferred stock — 32,706 — 23,469 — — — — 56,175 Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (13,674,365) (112,017) (9,197,142) (75,341) (32,746,041) (32,746) (42,560,530) (42,561) (262,665) Balance, January 31, 2020 — $ — $ — $ — $ — $ — $ — $ — $ — During the years ended January 31, 2022 and 2021, there were no new issuances of preferred stock, and there was no outstanding balance of preferred stock as of January 31, 2022 and 2021.

Equity-based compensation

Equity-based compensation	12 Months Ended
	Jan. 31, 2022
Share-based Payment Arrangement [Abstract]
Equity-based compensation	Equity-based compensation (a) Equity award plans In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and will automatically increase each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2022 and 2021 were made pursuant to the 2019 plan, respectively. (b) Summary of stock-based compensation The following table sets forth stock-based compensation by type of award: For the fiscal years ended 2022 2021 2020 RSUs $ 24,222 $ 10,693 $ 3,397 Liability awards 7,055 — — PSUs 2,389 93 — Stock options 2,294 2,703 2,780 ESPP 763 — — Total stock-based compensation $ 36,723 $ 13,489 $ 6,177 The following table sets forth the presentation of stock-based compensation in the Company's financial statements: For the fiscal years ended 2022 2021 2020 Stock-based compensation expense recorded to additional paid-in capital (1) $ 29,668 $ 13,489 $ 6,177 Stock-based compensation expense recorded to accrued expenses 7,055 — — Total stock-based compensation 36,723 13,489 6,177 Less stock-based compensation expense capitalized as internal-use software (489) — — Stock-based compensation expense per consolidated statements of operations (2) $ 36,234 $ 13,489 $ 6,177 (1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts. (2) Non-cash stock-based compensation expense included in the Company's consolidated statements of cash flows is $36,144, and excludes $90 of cash-settled stock-based compensation expense included in the Company's statements of operations. (c) Restricted stock units During fiscal 2020, prior to the IPO, the Company issued restricted stock units to employees and directors that vest based on both a time-based condition and a performance-based condition. Pursuant to the time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The performance-based condition was based on a sale of the Company or an IPO, as defined therein. The restricted stock units expire seven years from the grant date. Upon completion of the Company’s IPO in July 2019, the Company immediately recognized the fair value of the vested units with the unvested portion recognized over the remaining service period. In addition, in August 2019, the compensation committee of the Board of Directors approved allowing executive officers the ability to elect to receive all or a portion of the bonus (based on its target bonus opportunity for the last half of the fiscal year) in the form of restricted stock units instead of cash. For such executive officers that elected to receive restricted stock units, such award was granted immediately after such election with a value equal to the portion of the target bonus opportunity that the executive officer elected not to receive in cash, and such award vests based on the achievement of the Company’s predefined performance targets. These performance-based awards were released in April 2020, after final approval by the Compensation Committee. The Company has issued restricted stock units to employees and directors that vest based on a time-based condition. For RSUs granted prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The restricted stock units expire seven years from the grant date. During the year ended January 31, 2022, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its most recent proxy statement ("NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For NEOs and other members of the Company's executive management team, RSUs granted after January 1, 2022 vest 6.25% each quarter over four years based on continued service. Restricted stock units Unvested, February 1, 2019 20,164 Granted during year 1,493,678 Vested (43,011) Forfeited and expired (23,413) Unvested, February 1, 2020 1,447,418 Granted during year 972,271 Vested (242,049) Forfeited and expired (124,602) Unvested, January 31, 2021 2,053,038 Granted during year 1,836,534 Vested (559,767) Forfeited and expired (195,966) Unvested, January 31, 2022 3,133,839 As of January 31, 2022, there is $102,442 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 3.2 years. For the years ended January 31, 2022, 2021 and 2020, the weighted average grant date fair value of restricted stock units granted was $46.60, $32.78 and $21.31 respectively. (d) Stock options Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis. The fair value of stock options is estimated on the date of the grant using the Black-Scholes option pricing model for each of the stock option awards granted. The assumptions are provided below. Expected volatility was based on the stock volatility for comparable publicly traded companies. The Company uses the simplified method as described in SEC Staff Accounting Bulletin (SAB) 107 to estimate the expected life of stock options. Forfeitures are recorded when they occur. The risk-free rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. The Company did not grant any options during the years ended January 31, 2022 and 2021. Fiscal year ended 2020 Risk-free interest rate 2.18 % Expected dividends none Expected term (in years) 6.25 Volatility 45.15 % Weighted average fair value of grants $ 4.99 Stock option activity for the fiscal years ended January 31, 2022, 2021 and 2020 is as follows: Number of Weighted- Weighted- Aggregate Intrinsic Outstanding—January 31, 2019 5,055,505 $ 2.45 Granted during the year 1,230,382 $ 8.78 Exercised (691,371) $ 2.62 Forfeited (78,064) $ 5.20 Outstanding and expected to vest — January 31, 2020 5,516,452 $ 3.80 6.22 $ 150,152 Outstanding—January 31, 2020 5,516,452 $ 3.80 Granted during the year — $ — Exercised (2,216,368) $ 2.39 Forfeited and expired (88,730) $ 7.45 Outstanding and expected to vest — January 31, 2021 3,211,354 $ 4.67 5.99 $ 194,676 Outstanding—January 31, 2021 3,211,354 $ 4.67 Granted during the year — $ — Exercised (1,439,186) $ 2.88 Forfeited and expired (67,018) $ 9.02 Outstanding and expected to vest — January 31, 2022 1,705,150 $ 6.01 5.94 $ 42,938 Exercisable — January 31, 2022 1,419,497 $ 5.46 5.69 $ 36,519 Amount vested during year ended January 31, 2022 551,341 $ 6.56 The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2022, 2021 and 2020 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $73,624, $33,575 and $13,960, respectively. As of January 31, 2022, there is $1,415 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 0.99 years. For the year ended January 31, 2022, stock-based compensation expense for stock options includes $363 related to the modification of stock options. (e) TSR performance-based restricted stock units (PSUs) The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Peer Group. Depending on the percentage level at which the market- based condition is satisfied, the number of shares vesting could be between 0% and 200% of the number of PSUs originally granted. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%. The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period. Fiscal years ended 2022 2021 Correlation coefficient 0.3878 0.4230 Valuation date stock price $ 36.03 $ 62.96 Simulation term 2.99 Years 3.00 Years Volatility 44.32 % 43.71 % Risk-free rate 1.23 % 0.20 % Dividend yield — % — % Weighted average fair value of grants $ 48.47 $ 84.38 Performance Outstanding February 1, 2020 — Granted during the year ended January 31, 2021 70,806 Outstanding, February 1, 2021 70,806 Granted during the year ended January 31, 2022 325,410 Vested — Forfeited and expired — Outstanding, January 31, 2022 396,216 As of January 31, 2022, unrecognized compensation cost for the PSUs was $19,265, to be recognized on a straight-line basis over 2.7 years, subject to the participants' continued employment with the Company. (f) Employee stock purchase plan The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986. Year ended Risk-free interest rate 0.17 % Expected dividends none Expected term (in years) 0.49 years Volatility 55.7 % In January 2022, the Company issued 42,530 shares of common stock for the ESPP purchase period ended on December 31, 2021. In connection with this issuance, the Company recorded a $1,506 increase to additional paid-in capital within stockholders' equity. As of January 31, 2022, unrecognized compensation cost related to the ESPP was $830, to be recognized over the next five months. (g) Liability awards In August 2021, the Company approved allowing eligible employees to elect to receive all or a portion of their fiscal 2022 year end bonus in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Bonuses to be settled in shares will be settled at a value equal to 115% of the bonuses converted. These share settled bonuses vest based on the achievement of the Company’s predefined performance targets. The immediately vested restricted stock units will be issued in April 2022, after final approval by the Compensation Committee of the Board of Directors. As the share settled bonuses will be settled in a variable number of shares, the Company has classified the share settled bonuses as a liability, which is included within accrued expenses on the accompanying consolidated balance sheet as of January 31, 2022. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense.

Fair value measurements

Fair value measurements	12 Months Ended
	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2022 Money market mutual funds $ 197,601 $ — $ — $ 197,601 Total assets $ 197,601 $ — $ — $ 197,601 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2021 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2021 Money market mutual funds $ 197,522 $ — $ — $ 197,522 Foreign currency derivative contracts — 148 — 148 Total assets $ 197,522 $ 148 $ — $ 197,670 Acquisition related contingent consideration liabilities $ — $ — $ (1,286) $ (1,286) Total liabilities $ — $ — $ (1,286) $ (1,286) The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The carrying value of the Company's debt approximates fair value because the interest rates approximate market rates and the debt maturities are relatively short-term. The Company used certain derivative financial instruments as part of its risk management strategy to reduce its foreign currency risk. The Company does not designate any derivatives as hedges in accordance with ASC 815 Derivatives and Hedging . The Company recognized all derivatives on the consolidated balance sheet at fair value based on quotes obtained from financial institutions. The fair value of its foreign currency forward contracts as of January 31, 2021 was an asset of $148, which was included in prepaid and other current assets on the accompanying consolidated balance sheet. The fair value of the foreign currency forward contracts were considered Level 2 in the fair value hierarchy as of January 31, 2021. The foreign currency forward contracts matured during the year ended January 31, 2022, and no foreign currency forward contracts remain outstanding as of January 31, 2022. In connection with the QueueDr acquisition, the Company recorded contingent consideration liabilities within accrued expenses on the accompanying consolidated balance sheet as of January 31, 2021 for amounts payable to the selling shareholders based on collections from QueueDr customers. The Company was required to pay the selling shareholders a multiple of the amount collected on certain customer contracts through November 2022. Certain payments are reduced to the amount of customer collections if the customer contract is canceled. The fair value of the Company's contingent consideration liabilities was determined using estimated cash flows and likelihoods of contract cancellation to estimate the expected payout based on collections and active status of the underlying customer contracts. The fair value of the Company's contingent consideration liabilities was determined based on inputs which are not readily available in public markets. Therefore, the Company categorized the liabilities as Level 3 in the fair value hierarchy. Based on the performance of the underlying customer contracts, the Company paid the maximum amount payable on the contingent consideration liabilities during the fiscal years ended January 31, 2021 and 2022. The following table presents a roll-forward of our contingent consideration liabilities: Balance at acquisition date $ 2,240 Change in fair value recognized in earnings 71 Settlements (1,025) Balance at January 31, 2021 1,286 Change in fair value recognized in earnings 258 Settlements (1,544) Balance at January 31, 2022 $ — The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the years ended January 31, 2022 and 2021.

Leases

Leases	12 Months Ended
	Jan. 31, 2022
Leases [Abstract]
Leases	Leases (a) Phreesia as Lessee The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. The Company's principal offices are located in Raleigh, North Carolina. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The operating lease right-of-use assets were calculated as the present value of operating lease liabilities, less the amount of unamortized tenant improvement allowance and deferred rent. The discount rate used was the Company’s incremental borrowing rate given that the implicit rate to each lease was not readily determinable. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two Supplemental balance sheet information related to operating and finance leases as of January 31, 2022 and 2021 was as follows: January 31, 2022 2021 Operating leases: Lease right-of-use assets $ 2,337 $ 2,654 Lease liabilities, current 1,281 1,087 Lease liabilities, non-current 1,276 1,899 Total operating lease liabilities $ 2,557 $ 2,986 Finance leases: Property and equipment, at cost $ 27,310 $ 19,933 Accumulated depreciation (15,025) (10,389) Property and equipment, net $ 12,285 $ 9,544 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 5,600 3,820 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 7,284 5,882 Total finance lease liabilities $ 12,884 $ 9,702 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of January 31, 2022, for operating leases, the weighted-average remaining lease term is 2.2 years and the weighted-average discount rate is 3.5%. As of January 31, 2022, for finance leases, the weighted-average remaining lease term is 2.5 years, and the weighted-average discount rate is 3.7%. The components of lease expense for the years ended January 31, 2022 and 2021 were as follows: Fiscal years ended 2022 2021 Operating leases: Operating lease cost $ 1,096 $ 1,766 Variable lease cost 223 257 Total operating lease cost $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 4,636 $ 2,876 Interest on lease liabilities 378 326 Total finance lease cost $ 5,014 $ 3,202 The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2022: January 31, 2022 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2023 $ 1,348 $ 5,956 2024 960 4,894 2025 225 2,444 2026 86 158 2027 42 — Total future minimum lease payments $ 2,661 $ 13,452 Less: interest (104) (568) Present value of lease liabilities $ 2,557 $ 12,884 Other supplemental cash flow information for the year ended January 31, 2022 and 2021 was as follows: Fiscal years ended 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,206 $ 1,629 Operating cash used for finance leases 377 326 Financing cash used for finance leases 4,267 2,630 Total $ 5,850 $ 4,585 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the years ended January 31, 2022 and 2021 the Company recognized $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. The Company's principal offices are located in Raleigh, North Carolina. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The operating lease right-of-use assets were calculated as the present value of operating lease liabilities, less the amount of unamortized tenant improvement allowance and deferred rent. The discount rate used was the Company’s incremental borrowing rate given that the implicit rate to each lease was not readily determinable. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two Supplemental balance sheet information related to operating and finance leases as of January 31, 2022 and 2021 was as follows: January 31, 2022 2021 Operating leases: Lease right-of-use assets $ 2,337 $ 2,654 Lease liabilities, current 1,281 1,087 Lease liabilities, non-current 1,276 1,899 Total operating lease liabilities $ 2,557 $ 2,986 Finance leases: Property and equipment, at cost $ 27,310 $ 19,933 Accumulated depreciation (15,025) (10,389) Property and equipment, net $ 12,285 $ 9,544 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 5,600 3,820 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 7,284 5,882 Total finance lease liabilities $ 12,884 $ 9,702 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of January 31, 2022, for operating leases, the weighted-average remaining lease term is 2.2 years and the weighted-average discount rate is 3.5%. As of January 31, 2022, for finance leases, the weighted-average remaining lease term is 2.5 years, and the weighted-average discount rate is 3.7%. The components of lease expense for the years ended January 31, 2022 and 2021 were as follows: Fiscal years ended 2022 2021 Operating leases: Operating lease cost $ 1,096 $ 1,766 Variable lease cost 223 257 Total operating lease cost $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 4,636 $ 2,876 Interest on lease liabilities 378 326 Total finance lease cost $ 5,014 $ 3,202 The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2022: January 31, 2022 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2023 $ 1,348 $ 5,956 2024 960 4,894 2025 225 2,444 2026 86 158 2027 42 — Total future minimum lease payments $ 2,661 $ 13,452 Less: interest (104) (568) Present value of lease liabilities $ 2,557 $ 12,884 Other supplemental cash flow information for the year ended January 31, 2022 and 2021 was as follows: Fiscal years ended 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,206 $ 1,629 Operating cash used for finance leases 377 326 Financing cash used for finance leases 4,267 2,630 Total $ 5,850 $ 4,585 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the years ended January 31, 2022 and 2021 the Company recognized $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. The Company's principal offices are located in Raleigh, North Carolina. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The operating lease right-of-use assets were calculated as the present value of operating lease liabilities, less the amount of unamortized tenant improvement allowance and deferred rent. The discount rate used was the Company’s incremental borrowing rate given that the implicit rate to each lease was not readily determinable. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two Supplemental balance sheet information related to operating and finance leases as of January 31, 2022 and 2021 was as follows: January 31, 2022 2021 Operating leases: Lease right-of-use assets $ 2,337 $ 2,654 Lease liabilities, current 1,281 1,087 Lease liabilities, non-current 1,276 1,899 Total operating lease liabilities $ 2,557 $ 2,986 Finance leases: Property and equipment, at cost $ 27,310 $ 19,933 Accumulated depreciation (15,025) (10,389) Property and equipment, net $ 12,285 $ 9,544 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 5,600 3,820 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 7,284 5,882 Total finance lease liabilities $ 12,884 $ 9,702 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of January 31, 2022, for operating leases, the weighted-average remaining lease term is 2.2 years and the weighted-average discount rate is 3.5%. As of January 31, 2022, for finance leases, the weighted-average remaining lease term is 2.5 years, and the weighted-average discount rate is 3.7%. The components of lease expense for the years ended January 31, 2022 and 2021 were as follows: Fiscal years ended 2022 2021 Operating leases: Operating lease cost $ 1,096 $ 1,766 Variable lease cost 223 257 Total operating lease cost $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 4,636 $ 2,876 Interest on lease liabilities 378 326 Total finance lease cost $ 5,014 $ 3,202 The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2022: January 31, 2022 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2023 $ 1,348 $ 5,956 2024 960 4,894 2025 225 2,444 2026 86 158 2027 42 — Total future minimum lease payments $ 2,661 $ 13,452 Less: interest (104) (568) Present value of lease liabilities $ 2,557 $ 12,884 Other supplemental cash flow information for the year ended January 31, 2022 and 2021 was as follows: Fiscal years ended 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,206 $ 1,629 Operating cash used for finance leases 377 326 Financing cash used for finance leases 4,267 2,630 Total $ 5,850 $ 4,585 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the years ended January 31, 2022 and 2021 the Company recognized $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies (a) Indemnifications The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued a ny liabilities related to such obligations in our consolidated financial statements. In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceedi n g to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows. (c) Contingent consideration for acquisitions Consideration transferred for the QueueDr acquisition included consideration payable contingent upon future events. The Company recorded a $1,286 contingent consideration liability on its consolidated balance sheet as of January 31, 2021, which was payable based upon the performance of certain acquired customer contracts. The Company paid $1,544 to settle the liability during the year ended January 31, 2022, and no liability remains outstanding as of January 31, 2022. See Note 16 - Acquisitions for additional discussion regarding contingent consideration. (d) Other contractual commitments Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2022 are presented in the table below. Purchase obligations Year ending January 31, 2023 $ 6,638 2024 7,200 2025 3,261 2026 810 Thereafter 150 Total $ 18,059

Income taxes

Income taxes	12 Months Ended
	Jan. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income taxes For the year ended January 31, 2022, the Company recorded a tax provision of $182, compared to a tax provision of $49, for the corresponding period in the prior year. Our provision for income taxes was 0.2% and 0.2% of loss before income taxes for the year ended January 31, 2022 and 2021, respectively. Our benefit from income taxes was 8.1% of loss before income taxes for the year ended January 31, 2020. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against the majority of its deferred tax assets, and due to foreign income tax expense recorded for the Company's Canada branch related to the use of net operating loss carry forwards to offset current income. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2022 and January 31, 2021. The Company’s loss before income taxes was primarily generated in the United States for fiscal 2022, fiscal 2021 and fiscal 2020. The Company's income tax provision (benefit) consisted of the following for fiscal 2022, 2021 and 2020: Fiscal years ended January 31, 2022 2021 2020 Current tax Federal $ — $ — $ — State 39 114 — Foreign — — (1,005) Deferred tax Federal — (116) — State — (65) — Foreign 143 116 (775) Total provision for (benefit from) income taxes $ 182 $ 49 $ (1,780) A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2022, 2021 and 2020 is as follows: Fiscal years ended January 31, 2022 2021 2020 Federal income tax benefit at statutory rate 21 % 21 % 21 % State and local tax, net of federal benefit 9 % 10 % 3 % Permanent differences — % — % (2) % Equity compensation 6 % 44 % 7 % Foreign taxes — % — % 8 % Other — % (4) % (4) % Change in valuation allowance (36) % (71) % (25) % Effective income tax rate — % — % 8 % January 31, Deferred tax assets (liabilities) 2022 2021 Net operating loss carryforwards $ 88,979 $ 51,973 Stock based compensation 5,374 1,162 Accruals, reserves, and other expenses 3,697 2,823 Reserve for bad debts 521 443 Disallowed interest expense 1,934 1,586 Total deferred tax assets 100,505 57,987 Less valuation allowance (97,279) (54,563) Net deferred tax assets 3,226 3,424 Depreciation and amortization (1,250) (1,568) Intangible assets (373) (440) Deferred contract acquisition costs (1,088) (758) Total deferred tax liabilities (2,711) (2,766) Deferred taxes, net $ 515 $ 658 The Company has accumulated a Federal net operating loss carryforward of approximately $332,544 and $199,079 as of January 31, 2022 and 2021, respectively. This carryforward may be available to offset future income tax liabilities and will expire beginning in 2025. As of January 31, 2022, the Company's foreign branch had net operating loss carryforwards of approximately $1,943, which may be available to offset future income in Canada and will expire beginning in 2030. Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized. On the basis of this evaluation, as of January 31, 2022 and 2021, the Company recorded a valuation allowance of $97,279 and $54,563, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $42,716 increase in the valuation allowance recorded during the fiscal year ended January 31, 2022 relates primarily to deferred tax assets established and recorded during the fiscal year ended January 31, 2022. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced. Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2022, the Company has U.S. net operating loss carryforwards of approximately $332.5 million. The Company has completed a Section 382 study and as a result of the analysis, it is more likely than not that the Company has experienced an “ownership change”. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership. Accordingly, if the Company earns net taxable income, it is more likely than not that the Company's ability to use its pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2018 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2022 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets in accordance with ASC 740 and adjusts these balances when its judgement changes as a result of the evaluation of new information previously not available. The Company recognized interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions. The following is a roll forward of the Company's total gross unrecognized tax benefits: January 31, 2022 2021 2020 Unrecognized income tax benefits, opening balance $ — $ — $ 1,000 Increase for income tax positions of prior years — — — Lapse of statute of limitations — — (1,000) Unrecognized income tax benefits, ending balance $ — $ — $ —

Net loss per share attributable

Net loss per share attributable to common stockholders	12 Months Ended
	Jan. 31, 2022
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	Net loss per share attributable to common stockholders (a) Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Fiscal years ended January 31, 2022 2021 2020 Numerator: Net loss $ (118,161) $ (27,292) $ (20,293) Preferred stock dividend paid — — (14,955) Accretion of redeemable convertible preferred stock to redemption value — — (56,175) Net loss attributable to common stockholders $ (118,161) $ (27,292) $ (91,423) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 49,888,436 39,519,640 20,301,189 Net loss per share attributable to common stockholders $ (2.37) $ (0.69) $ (4.50) (b) Potential dilutive securities The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock units, grants under the Company's ESPP and outstanding warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Fiscal years ended January 31, 2022 2021 2020 Stock options to purchase common stock, restricted stock units and performance stock units 5,632,823 5,406,004 6,963,870 Employee stock purchase plan 75,370 — — Warrants to purchase common stock — — 75,137 Total 5,708,193 5,406,004 7,039,007

Retirement savings plan

Retirement savings plan	12 Months Ended
	Jan. 31, 2022
Retirement Benefits [Abstract]
Retirement savings plan	Retirement savings planOn February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in years ended January 31, 2022, 2021 or 2020

Related party transactions

Related party transactions	12 Months Ended
	Jan. 31, 2022
Related Party Transactions [Abstract]
Related party transactions	Related party transactions For the year ended January 31, 2022, the Company recognized revenue totaling $482 for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. For the years ended January 31, 2022 and 2021, accounts receivable from the pharmaceutical company totaled $173 and $68, respectively. On September 29, 2021, the Company appointed a new independent member to its board of directors, effective October 1, 2021. The new board member is the chief executive officer and serves on the board of directors of a software company that has received payments from the Company pursuant to an existing software agreement since February 1, 2020. During the period from October 1, 2021 through January 31, 2022, the Company paid $412 to this software company. The Company has included $374 and $51 of payments to this software company within prepaid expenses and other current assets and other assets, respectively, in its consolidated balance sheet as of January 31, 2022. During the period from October 1, 2021 through January 31, 2022, the Company has included $182 of expenses related to the agreement with this software company within General and administrative expenses in its consolidated statement of operations for the year ended January 31, 2022.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Acquisition of Insignia Health, LLC On December 3, 2021, the Company entered into an agreement to acquire 100% of the outstanding equity of Insignia, a founder-led and mission-oriented company for cash consideration of $37,208. Insignia provides coaching and education solutions in conjunction with Insignia's exclusive worldwide license to the PAM. The PAM is a survey measuring a patient's knowledge, skills and ability to manage their care. The Company acquired Insignia to enable the Company to understand and engage patients in more personalized ways based on their level of activation. The acquisition of Insignia was accounted for as a business combination. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid to sellers $ 37,112 Liabilities incurred to sellers 96 Total fair value of acquisition consideration $ 37,208 Cash consideration paid to sellers $ 37,112 Less: Cash acquired (2,689) Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows $ 34,423 The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations. Cash $ 2,689 Accounts receivable 994 Prepaid expenses and other assets 358 Operating lease right-of-use assets 606 Intangibles 10,700 Goodwill 25,410 Total assets acquired 40,757 Accounts payable (84) Accrued liabilities (487) Deferred revenue (2,372) Operating lease liabilities (606) Total purchase price $ 37,208 The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value PAM license 15 $ 6,200 Customer relationships 10 4,500 Total identifiable intangible assets acquired $ 10,700 The weighted average amortization period for acquired intangible assets as of the date of acquisition is 13 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Insignia. The fair value of the acquired PAM license was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes. The goodwill recognized in the acquisition of Insignia is primarily attributable to expected synergies of the combined businesses driven by integrating the PAM into the Phreesia Platform and engaging with patients in more personalized ways based on their level of activation, as well as the acquisition of an assembled workforce. The goodwill is not expected to be deductible for tax purposes. On January 8, 2021, the Company entered into a stock purchase agreement with QueueDr to acquire 100% of the outstanding equity of QueueDr, an early-stage software company that automates the process of rescheduling cancellations and no-shows. We acquired QueueDr to enhance our appointments solution. The total acquisition-date fair value of consideration transferred for the acquisition consisted of $5.8 million in cash, $2.1 million of liabilities incurred and $2.2 million in performance-related contingent payments. The acquisition of QueueDr was accounted for as a business combination. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid on acquisition date $ 5,773 Liabilities incurred 2,111 Contingent consideration 2,240 Total fair value of acquisition consideration $ 10,124 The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021: Cash consideration paid on acquisition date $ 5,773 Payments of acquisition date fair value of contingent consideration 954 Less cash acquired (217) Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows $ 6,510 Liabilities incurred were primarily related to hold-backs for general representations and warranties. The maximum amount payable for contingent consideration was $2,574, based upon the performance of certain customer contracts. The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimated fair values. The following table summarizes the final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Cash $ 217 Accounts receivable 455 Other current assets 192 Identified intangible assets acquired 1,780 Deferred tax asset 262 Goodwill 8,057 Other assets 223 Total assets acquired 11,186 Accounts payable (86) Accrued liabilities (254) Deferred revenue (55) Long-term debt (223) Deferred tax liability (444) Total purchase price $ 10,124 The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value Acquired technology 5 $ 920 Customer relationships 10 860 Total identifiable intangible assets acquired $ 1,780 The weighted average amortization period for acquired intangible assets as of the date of acquisition was 7.4 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of QueueDr. The fair value of the acquired technology was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each client grouping. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes. The goodwill recognized in the acquisition of QueueDr is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce. The goodwill is not expected to be deductible for tax purposes.

Subsequent events

Subsequent events	12 Months Ended
	Jan. 31, 2022
Subsequent Events [Abstract]
Subsequent events	Subsequent events On March 28, 2022, the Company entered into the Third SVB Facility to increase the available revolving line of credit to $100 million. Borrowings under the Third SVB Facility are payable on May 5, 2025. Borrowings under the Third SVB Facility bear interest, which is payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.50%. In addition to principal and interest due under the Third SVB Facility, the Company is required to pay an annual commitment fee of approximately $0.3 million per year, plus an annual fee equal to 0.15% of the unused balance of the facility, payable quarterly.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Consolidated Financial StatementsThe accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company").
Fiscal year	Fiscal yearThe Company’s fiscal year ends on January 31. References to fiscal 2022, 2021 and 2020, refer to the fiscal years ended January 31, 2022, 2021 and 2020, respectively.
Use of estimates	Use of estimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.
Revenue recognition	Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers , as well as for additional details about the Company's products and service lines.
Concentrations of credit risk and risks and uncertainties	Concentrations of credit riskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two Risks Related to the COVID-19 Pandemic In March 2020, the World Health Organization declared the ongoing outbreak of a novel strain of coronavirus ("COVID-19") a pandemic. There continues to be uncertainty as to the duration and extent to which the global COVID-19 pandemic, as well as the emergence of new variants, may adversely impact the Company's business operations, financial performance, and results of operations, as well as macroeconomic conditions, at this time. Other Risks and Uncertainties The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third party vendors, partners, and service providers. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of our business and our customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of our operations, adversely impacting the Company’s operating results and our ability to meet our obligations and commitments. See Note 6 - Finance leases and other debt, for a summary of our contractual commitments as of January 31, 2022.
Cost of revenue (excluding depreciation and amortization)	Cost of revenue (excluding depreciation and amortization)Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
Payment processing expense	Payment processing expensePayment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways.
Sales and marketing	Sales and marketingSales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred.
Research and development	Research and developmentResearch and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
General and administrative	General and administrativeGeneral and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation and amortization	DepreciationDepreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.AmortizationAmortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
Cash and cash equivalents	Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market account meets the definition of cash equivalents.
Settlement assets	Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two
Settlement obligations	Settlement obligationsSettlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
Accounts receivable	Accounts receivableAccounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2022 and 2021, the Company has reserved $863 and $699, respectively, for the allowance for doubtful accounts.
Property and equipment	Property and equipment Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
Capitalized internal-use software	Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three
Business combinations	Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations. When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.
Goodwill and intangible assets	Goodwill and intangible assets Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount. All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long-lived assets	Long-lived assetsLong-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Income taxes	Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
Segment information	Segment informationOperating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements.
Stock-based compensation	Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718 , Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares
Fair value of financial instruments	Fair value of financial instruments Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Equity offering costs	Equity offering costsThe Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations.
Foreign currency	Foreign currencyThe Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net.
New accounting pronouncements	New accounting pronouncements Impact of recently adopted accounting pronouncements In October 2021, the FASB issued ASU No. 2021-08, Business Combinations - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update creates an exception to the recognition and measurement principles in ASC 805, Business Combinations. The amendments require an acquirer to recognize and measure contracts assets and liabilities related to customer contracts acquired in a business combination under the guidance in ASC 606, Revenue from Contracts with Customers, rather than using fair value. The Company adopted the new guidance for the fiscal year ended January 31, 2022 and applied the new guidance to the acquisition of Insignia Health, LLC, ("Insignia") which occurred during the year ended January 31, 2022. For the acquisition of Insignia, the Company recognized and measured acquired deferred revenue in accordance with ASC 606. The Company measured acquired deferred revenue as if the Company had originated the related acquired customer contracts. In accordance with practical expedients available in ASU 2021-08, the Company reflected in acquired deferred revenue the aggregate effect of all contract modifications that occurred prior to the acquisition date, and the Company determined the standalone selling price of each performance obligation included in acquired deferred revenue as of the acquisition date. The effect of applying the practical expedients was not significant. See Note 16 - Acquisitions for additional information regarding the acquisition of Insignia. On February 1, 2020, the Company adopted ASU No. 2016-02, Leases (Topic 842) which requires lessees to record most leases on their balance sheets but to recognize the expenses in their statement of operations in a manner similar to the prior standard. Topic 842 states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The Company adopted the new lease guidance using a modified retrospective transition method applied to those leases which were not completed as of February 1, 2020. As a result, the Company was not required to adjust its comparative period financial information for effects of the standard or make the new required lease disclosures for the periods before the date of adoption. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all of its leases. This means, for those leases that qualify, the Company will not recognize right-of-use assets or lease liabilities, including existing short-term leases as of the transition date. The Company also elected the practical expedient to not separate lease and non-lease components for its office and computer equipment leases. Upon adoption of Topic 842 the Company recognized operating lease right-of-use assets and operating lease liabilities related to its office leases of $2,741 and $2,928, respectively. The Company’s accounting for lessee finance and all lessor leases remains substantially unchanged from legacy guidance. The standard did not have a significant impact on the Company's statements of operations or statements of cash flows. No adjustment to accumulated deficit was recorded because the adoption did not change the Company's net assets. Recent accounting pronouncements not yet adopted There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	12 Months Ended
	Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]
Schedule of accrued expenses	Accrued expenses at January 31, 2022 and 2021 are as follows: January 31, 2022 2021 Payroll-related expenses and taxes $ 10,780 $ 8,946 Payment processing fees liability 3,502 2,853 Acquisition-related liabilities 96 3,386 Tax liabilities 2,093 700 Other 3,657 2,439 Total $ 20,128 $ 18,324
Schedule of property and equipment	Property and equipment at January 31, 2022 and 2021 are as follows: Useful life January 31, 2022 2021 PhreesiaPads and Arrivals Kiosks 3 $ 26,387 $ 25,837 Computer equipment 3 53,957 33,558 Computer software 3 to 5 5,311 5,105 Hardware development 3 1,024 1,024 Furniture and fixtures 7 539 539 Leasehold improvements 2 748 745 Total property and equipment $ 87,966 $ 66,808 Less accumulated depreciation (53,321) (40,148) Property and equipment — net $ 34,645 $ 26,660
Schedule of intangible assets	The following presents the details of intangible assets as of January 31, 2022 and January 31, 2021. Useful Life January 31, (years) 2022 2021 Acquired technology 5 $ 1,410 $ 1,410 Customer relationship 7 to 10 6,340 1,840 License 15 6,200 — Total intangible assets, gross carrying value $ 13,950 $ 3,250 Less accumulated amortization (1,178) (525) Net carrying value $ 12,772 $ 2,725
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2022: January 31, 2022 2023 $ 1,371 2024 1,358 2025 1,273 2026 1,242 2027-Thereafter 7,528 Total $ 12,772
Schedule of goodwill	The following table presents a roll-forward of goodwill for the years ended January 31, 2020, 2021 and 2022: Balance at January 31, 2020 $ 250 Goodwill acquired during the year ended January 31, 2021 8,057 Balance at January 31, 2021 8,307 Goodwill acquired during the year ended January 31, 2022 25,314 Balance at January 31, 2022 $ 33,621
Schedule of accounts receivable	Accounts Receivable as of January 31, 2022 and 2021 are as follows: January 31, 2022 2021 Billed $ 40,733 $ 28,464 Unbilled 392 1,287 Total accounts receivable, gross 41,125 29,751 Less accounts receivable allowances (863) (699) Total accounts receivable $ 40,262 $ 29,052
Schedule of allowance for doubtful accounts	Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2021 and 2022: Balance, January 31, 2020 $ 943 Bad debt expense 454 Write-offs and adjustments (698) Balance, January 31, 2021 699 Bad debt expense 212 Write-offs and adjustments (48) Balance, January 31, 2022 $ 863
Schedule of prepaid and other current assets	Prepaid and other current assets as of January 31, 2022 and 2021 are as follows: January 31, 2022 2021 Prepaid software and business systems $ 3,738 $ 2,322 Prepaid PhreesiaPads — 18 Prepaid data center expenses 3,230 1,211 Prepaid insurance 1,924 1,311 Other prepaid expenses and other current assets 2,151 2,392 Total prepaid and other current assets $ 11,043 $ 7,254

Revenue and Contract Costs (Tab

Revenue and Contract Costs (Tables)	12 Months Ended
	Jan. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of rollforward of contract assets and contract liabilities	The following table represents a roll-forward of contract assets: January 31, 2022 2021 Beginning Balance $ 1,287 $ 676 Amount transferred to receivables from beginning balance of contract assets (1,287) (676) Increases in contract assets due to acquisitions 243 — Contract asset additions, net of reclassification to receivables 149 1,287 Ending Balance $ 392 $ 1,287 The following table represents a roll-forward of deferred revenue: January 31, 2022 2021 Beginning Balance $ 10,838 $ 5,401 Revenue recognized that was included in deferred revenue at the beginning of the period (10,838) (5,097) Revenue recognized that was not included in deferred revenue at the beginning of the period (18,334) (1,512) Increases in deferred revenue due to acquisitions 2,372 55 Increases due to invoicing prior to satisfaction of performance obligations 32,520 11,991 Ending Balance $ 16,558 $ 10,838
Schedule of deferred contract acquisition costs	The following table represents a roll-forward of deferred contract acquisition costs: January 31, 2022 2021 Beginning balance $ 2,941 $ 3,314 Additions to deferred contract acquisition costs 3,349 1,652 Amortization of deferred contract acquisition costs (2,211) (2,025) Ending balance 4,079 2,941 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,642 1,693 Deferred contract acquisition costs, non-current 2,437 1,248 Total deferred contract acquisition costs $ 4,079 $ 2,941

Finance leases and other debt (

Finance leases and other debt (Tables)	12 Months Ended
	Jan. 31, 2022
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of January 31, 2022 and 2021, the Company had the following outstanding finance leases and other debt balances: January 31, 2022 2021 Finance leases $ 12,884 $ 9,702 Financing arrangements 266 1,533 Accrued interest and payments 94 100 Total finance lease liabilities and other debt $ 13,244 $ 11,335 Less - current portion of finance lease liabilities and other debt (5,821) (4,864) Long-term finance leases and other debt $ 7,423 $ 6,471
Schedule of long-term debt and finance lease maturities	Maturities of finance leases and other debt in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt Fiscal year ending January 31: 2023 $ 5,821 $ 5,600 $ 221 2024 4,866 4,727 139 2025 2,401 2,401 — 2026 156 156 — 2027 — — — Total maturities of finance leases and other debt $ 13,244 $ 12,884 $ 360
Schedule of components of interest income (expense)	The following table presents the components of interest (expense) income, net: Fiscal years ended January 31, 2022 2021 2020 Interest expense (1) $ (1,163) $ (1,695) $ (3,043) Interest income 79 122 598 Interest (expense) income, net $ (1,084) $ (1,573) $ (2,445) (1) Includes amortization of deferred financing costs and original issue discount

Stockholders' Equity and Pref_2

Stockholders' Equity and Preferred Stock (Tables)	12 Months Ended
	Jan. 31, 2022
Equity [Abstract]
Schedule of Changes in Preferred Stock	The following table summarizes changes in the Company's Series A Convertible Preferred and Redeemable Preferred for the fiscal year ended January 31, 2020: Redeemable preferred stock Senior A Senior B Junior Redeemable Shares Amount Shares Amount Shares Amount Shares Amounts Total Balance, January 31, 2019 13,674,365 $ 79,311 9,197,142 $ 51,872 32,746,041 $ 32,746 42,560,530 $ 42,561 $ 206,490 Accretion of redeemable preferred stock — 32,706 — 23,469 — — — — 56,175 Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (13,674,365) (112,017) (9,197,142) (75,341) (32,746,041) (32,746) (42,560,530) (42,561) (262,665) Balance, January 31, 2020 — $ — $ — $ — $ — $ — $ — $ — $ —

Equity-based compensation (Tabl

Equity-based compensation (Tables)	12 Months Ended
	Jan. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of stock based compensation by type of award	The following table sets forth stock-based compensation by type of award: For the fiscal years ended 2022 2021 2020 RSUs $ 24,222 $ 10,693 $ 3,397 Liability awards 7,055 — — PSUs 2,389 93 — Stock options 2,294 2,703 2,780 ESPP 763 — — Total stock-based compensation $ 36,723 $ 13,489 $ 6,177
Schedule of stock based compensation in financial statements	The following table sets forth the presentation of stock-based compensation in the Company's financial statements: For the fiscal years ended 2022 2021 2020 Stock-based compensation expense recorded to additional paid-in capital (1) $ 29,668 $ 13,489 $ 6,177 Stock-based compensation expense recorded to accrued expenses 7,055 — — Total stock-based compensation 36,723 13,489 6,177 Less stock-based compensation expense capitalized as internal-use software (489) — — Stock-based compensation expense per consolidated statements of operations (2) $ 36,234 $ 13,489 $ 6,177 (1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts. (2) Non-cash stock-based compensation expense included in the Company's consolidated statements of cash flows is $36,144, and excludes $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.
Schedule of restricted stock unit activity	Restricted stock units Unvested, February 1, 2019 20,164 Granted during year 1,493,678 Vested (43,011) Forfeited and expired (23,413) Unvested, February 1, 2020 1,447,418 Granted during year 972,271 Vested (242,049) Forfeited and expired (124,602) Unvested, January 31, 2021 2,053,038 Granted during year 1,836,534 Vested (559,767) Forfeited and expired (195,966) Unvested, January 31, 2022 3,133,839
Schedule of weighted average assumptions	Fiscal year ended 2020 Risk-free interest rate 2.18 % Expected dividends none Expected term (in years) 6.25 Volatility 45.15 % Weighted average fair value of grants $ 4.99
Schedule of stock option activity	Stock option activity for the fiscal years ended January 31, 2022, 2021 and 2020 is as follows: Number of Weighted- Weighted- Aggregate Intrinsic Outstanding—January 31, 2019 5,055,505 $ 2.45 Granted during the year 1,230,382 $ 8.78 Exercised (691,371) $ 2.62 Forfeited (78,064) $ 5.20 Outstanding and expected to vest — January 31, 2020 5,516,452 $ 3.80 6.22 $ 150,152 Outstanding—January 31, 2020 5,516,452 $ 3.80 Granted during the year — $ — Exercised (2,216,368) $ 2.39 Forfeited and expired (88,730) $ 7.45 Outstanding and expected to vest — January 31, 2021 3,211,354 $ 4.67 5.99 $ 194,676 Outstanding—January 31, 2021 3,211,354 $ 4.67 Granted during the year — $ — Exercised (1,439,186) $ 2.88 Forfeited and expired (67,018) $ 9.02 Outstanding and expected to vest — January 31, 2022 1,705,150 $ 6.01 5.94 $ 42,938 Exercisable — January 31, 2022 1,419,497 $ 5.46 5.69 $ 36,519 Amount vested during year ended January 31, 2022 551,341 $ 6.56
Schedule of measurement inputs and valuation techniques	Fiscal years ended 2022 2021 Correlation coefficient 0.3878 0.4230 Valuation date stock price $ 36.03 $ 62.96 Simulation term 2.99 Years 3.00 Years Volatility 44.32 % 43.71 % Risk-free rate 1.23 % 0.20 % Dividend yield — % — % Weighted average fair value of grants $ 48.47 $ 84.38
Schedule of market-based performance stock unit activity	Market based PSU activity for the years ended January 31, 2021 and 2022 are as follows: Performance Outstanding February 1, 2020 — Granted during the year ended January 31, 2021 70,806 Outstanding, February 1, 2021 70,806 Granted during the year ended January 31, 2022 325,410 Vested — Forfeited and expired — Outstanding, January 31, 2022 396,216
Schedule of ESPP valuation assumptions	The fair value of shares granted under the ESPP during the year ended January 31, 2022 was estimated using a Black-Scholes pricing model with the following assumptions: Year ended Risk-free interest rate 0.17 % Expected dividends none Expected term (in years) 0.49 years Volatility 55.7 %

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of fair value, assets and liabilities measured on recurring basis	The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2022 Money market mutual funds $ 197,601 $ — $ — $ 197,601 Total assets $ 197,601 $ — $ — $ 197,601 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2021 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2021 Money market mutual funds $ 197,522 $ — $ — $ 197,522 Foreign currency derivative contracts — 148 — 148 Total assets $ 197,522 $ 148 $ — $ 197,670 Acquisition related contingent consideration liabilities $ — $ — $ (1,286) $ (1,286) Total liabilities $ — $ — $ (1,286) $ (1,286)
Schedule of loss contingencies by contingency	The following table presents a roll-forward of our contingent consideration liabilities: Balance at acquisition date $ 2,240 Change in fair value recognized in earnings 71 Settlements (1,025) Balance at January 31, 2021 1,286 Change in fair value recognized in earnings 258 Settlements (1,544) Balance at January 31, 2022 $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jan. 31, 2022
Leases [Abstract]
Schedule of operating and finance leases	Supplemental balance sheet information related to operating and finance leases as of January 31, 2022 and 2021 was as follows: January 31, 2022 2021 Operating leases: Lease right-of-use assets $ 2,337 $ 2,654 Lease liabilities, current 1,281 1,087 Lease liabilities, non-current 1,276 1,899 Total operating lease liabilities $ 2,557 $ 2,986 Finance leases: Property and equipment, at cost $ 27,310 $ 19,933 Accumulated depreciation (15,025) (10,389) Property and equipment, net $ 12,285 $ 9,544 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 5,600 3,820 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 7,284 5,882 Total finance lease liabilities $ 12,884 $ 9,702
Schedule of lease expense and cash flow information	The components of lease expense for the years ended January 31, 2022 and 2021 were as follows: Fiscal years ended 2022 2021 Operating leases: Operating lease cost $ 1,096 $ 1,766 Variable lease cost 223 257 Total operating lease cost $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 4,636 $ 2,876 Interest on lease liabilities 378 326 Total finance lease cost $ 5,014 $ 3,202 Other supplemental cash flow information for the year ended January 31, 2022 and 2021 was as follows: Fiscal years ended 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,206 $ 1,629 Operating cash used for finance leases 377 326 Financing cash used for finance leases 4,267 2,630 Total $ 5,850 $ 4,585
Schedule of maturing lease commitments of operating leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2022: January 31, 2022 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2023 $ 1,348 $ 5,956 2024 960 4,894 2025 225 2,444 2026 86 158 2027 42 — Total future minimum lease payments $ 2,661 $ 13,452 Less: interest (104) (568) Present value of lease liabilities $ 2,557 $ 12,884
Schedule of maturing lease commitments of finance leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2022: January 31, 2022 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2023 $ 1,348 $ 5,956 2024 960 4,894 2025 225 2,444 2026 86 158 2027 42 — Total future minimum lease payments $ 2,661 $ 13,452 Less: interest (104) (568) Present value of lease liabilities $ 2,557 $ 12,884

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	12 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Minimum Payments Under Purchase Commitments	Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2022 are presented in the table below. Purchase obligations Year ending January 31, 2023 $ 6,638 2024 7,200 2025 3,261 2026 810 Thereafter 150 Total $ 18,059

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jan. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of income tax (benefit)	The Company's income tax provision (benefit) consisted of the following for fiscal 2022, 2021 and 2020: Fiscal years ended January 31, 2022 2021 2020 Current tax Federal $ — $ — $ — State 39 114 — Foreign — — (1,005) Deferred tax Federal — (116) — State — (65) — Foreign 143 116 (775) Total provision for (benefit from) income taxes $ 182 $ 49 $ (1,780)
Schedule of effective tax rate	A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2022, 2021 and 2020 is as follows: Fiscal years ended January 31, 2022 2021 2020 Federal income tax benefit at statutory rate 21 % 21 % 21 % State and local tax, net of federal benefit 9 % 10 % 3 % Permanent differences — % — % (2) % Equity compensation 6 % 44 % 7 % Foreign taxes — % — % 8 % Other — % (4) % (4) % Change in valuation allowance (36) % (71) % (25) % Effective income tax rate — % — % 8 %
Schedule of deferred tax assets and liabilities	January 31, Deferred tax assets (liabilities) 2022 2021 Net operating loss carryforwards $ 88,979 $ 51,973 Stock based compensation 5,374 1,162 Accruals, reserves, and other expenses 3,697 2,823 Reserve for bad debts 521 443 Disallowed interest expense 1,934 1,586 Total deferred tax assets 100,505 57,987 Less valuation allowance (97,279) (54,563) Net deferred tax assets 3,226 3,424 Depreciation and amortization (1,250) (1,568) Intangible assets (373) (440) Deferred contract acquisition costs (1,088) (758) Total deferred tax liabilities (2,711) (2,766) Deferred taxes, net $ 515 $ 658
Schedule of unrecognized tax benefits	The following is a roll forward of the Company's total gross unrecognized tax benefits: January 31, 2022 2021 2020 Unrecognized income tax benefits, opening balance $ — $ — $ 1,000 Increase for income tax positions of prior years — — — Lapse of statute of limitations — — (1,000) Unrecognized income tax benefits, ending balance $ — $ — $ —

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	12 Months Ended
	Jan. 31, 2022
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Fiscal years ended January 31, 2022 2021 2020 Numerator: Net loss $ (118,161) $ (27,292) $ (20,293) Preferred stock dividend paid — — (14,955) Accretion of redeemable convertible preferred stock to redemption value — — (56,175) Net loss attributable to common stockholders $ (118,161) $ (27,292) $ (91,423) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 49,888,436 39,519,640 20,301,189 Net loss per share attributable to common stockholders $ (2.37) $ (0.69) $ (4.50)
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Fiscal years ended January 31, 2022 2021 2020 Stock options to purchase common stock, restricted stock units and performance stock units 5,632,823 5,406,004 6,963,870 Employee stock purchase plan 75,370 — — Warrants to purchase common stock — — 75,137 Total 5,708,193 5,406,004 7,039,007

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jan. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of purchase price considerations at acquisition date	The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid to sellers $ 37,112 Liabilities incurred to sellers 96 Total fair value of acquisition consideration $ 37,208 Cash consideration paid to sellers $ 37,112 Less: Cash acquired (2,689) Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows $ 34,423 The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid on acquisition date $ 5,773 Liabilities incurred 2,111 Contingent consideration 2,240 Total fair value of acquisition consideration $ 10,124 The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021: Cash consideration paid on acquisition date $ 5,773 Payments of acquisition date fair value of contingent consideration 954 Less cash acquired (217) Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows $ 6,510
Schedule of allocation of purchase price of assets acquired and liabilities assumed	The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition: Cash $ 2,689 Accounts receivable 994 Prepaid expenses and other assets 358 Operating lease right-of-use assets 606 Intangibles 10,700 Goodwill 25,410 Total assets acquired 40,757 Accounts payable (84) Accrued liabilities (487) Deferred revenue (2,372) Operating lease liabilities (606) Total purchase price $ 37,208 The following table summarizes the final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Cash $ 217 Accounts receivable 455 Other current assets 192 Identified intangible assets acquired 1,780 Deferred tax asset 262 Goodwill 8,057 Other assets 223 Total assets acquired 11,186 Accounts payable (86) Accrued liabilities (254) Deferred revenue (55) Long-term debt (223) Deferred tax liability (444) Total purchase price $ 10,124
Schedule of intangible assets acquired	The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value PAM license 15 $ 6,200 Customer relationships 10 4,500 Total identifiable intangible assets acquired $ 10,700 The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value Acquired technology 5 $ 920 Customer relationships 10 860 Total identifiable intangible assets acquired $ 1,780

Background and liquidity (Detai

Background and liquidity (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Mar. 28, 2022	May 05, 2020
Debt Instrument [Line Items]
Number of months with sufficient funds to operate (in months)	12 months
Third SVB Facility | Revolving credit facility | Subsequent event
Debt Instrument [Line Items]
Line of credit borrowing capacity		$ 100,000
Second SVB Facility | Revolving credit facility
Debt Instrument [Line Items]
Line of credit borrowing capacity			$ 50,000

Summary of significant accoun_3

Summary of significant accounting policies (Details)	12 Months Ended
	Jan. 31, 2022USD ($)segmentprocessor	Jan. 31, 2021USD ($)	Jan. 31, 2020USD ($)	Feb. 01, 2020USD ($)
Accounting Policies [Line Items]
Number of third party payment processors | processor	1
Advertising expense	$ 4,007,000	$ 558,000	$ 251,000
Allowance for doubtful accounts	863,000	699,000	943,000
Asset impairment charges	$ 0	0	$ 0
Number of operating segment | segment	1
Operating lease right-of-use assets	$ 2,337,000	2,654,000
Operating lease liabilities	$ 2,557,000	$ 2,986,000
Topic 842
Accounting Policies [Line Items]
Operating lease right-of-use assets				$ 2,741,000
Operating lease liabilities				$ 2,928,000
ESPP
Accounting Policies [Line Items]
Employee purchase price of common stock (as a percent)	85.00%
Minimum
Accounting Policies [Line Items]
Customer payment period	30 days
Settlement period (in days)	1 day
Useful life (in years)	3 years
Minimum | Computer software
Accounting Policies [Line Items]
Estimated useful life (in years)	3 years
Minimum | Customer One | Revenue Benchmark | Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk (as a percent)	10.00%
Maximum
Accounting Policies [Line Items]
Customer payment period	60 days
Settlement period (in days)	2 days
Useful life (in years)	7 years
Maximum | Computer software
Accounting Policies [Line Items]
Estimated useful life (in years)	5 years

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Composition Of Certain Financial Statement [Abstract]
Payroll-related expenses and taxes	$ 10,780	$ 8,946
Payment processing fees liability	3,502	2,853
Acquisition-related liabilities	96	3,386
Tax liabilities	2,093	700
Other	3,657	2,439
Total	20,128	$ 18,324
Share-settled liabilities based on company performance	$ 7,500

Composition of certain financ_4

Composition of certain financial statement captions - Schedule of property and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 87,966	$ 66,808
Less accumulated depreciation	(53,321)	(40,148)
Property and equipment — net	$ 34,645	26,660
Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	7 years
PhreesiaPads and Arrivals Kiosks
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 26,387	25,837
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 53,957	33,558
Computer software
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 5,311	5,105
Computer software | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Computer software | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Hardware development
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 1,024	1,024
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life (in years)	7 years
Total property and equipment	$ 539	539
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life (in years)	2 years
Total property and equipment	$ 748	$ 745

Composition of certain financ_5

Composition of certain financial statement captions - Narrative (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Share-settled liabilities based on company performance	$ 7,500,000
Depreciation	14,985,000	$ 9,770,000	$ 8,753,000
Property and equipment, at cost	27,310,000	19,933,000
Assets under finance lease, accumulated amortization	15,025,000	10,389,000
Capitalized cost of computer software	12,830,000	7,663,000	5,852,000
Capitalized computed software amortization	5,664,000	5,884,000	4,933,000
Amortization of intangible assets	653,000	254,000	238,000
Impairment of goodwill	0	0	0
Goodwill adjustments during the year	25,314,000
Capitalized implementation costs	1,514,000
Capitalized implementation costs, accumulated amortization	199,000
Other (expense) income, net	(78,000)	1,000	(1,023,000)
Loss on extinguishment of debt	0	$ 0	$ 1,073,000
QueueDr
Finite-Lived Intangible Assets [Line Items]
Goodwill adjustments during the year	$ 96,000
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	3 years 6 months	4 years 4 months 24 days
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	9 years 2 months 12 days	7 years 8 months 12 days
License
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	14 years 9 months 18 days
Computer equipment
Finite-Lived Intangible Assets [Line Items]
Property and equipment, at cost	$ 27,310,000	$ 19,933,000
Assets under finance lease, accumulated amortization	$ 15,025,000	$ 10,389,000

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 13,950	$ 3,250
Less accumulated amortization	(1,178)	(525)
Net carrying value	$ 12,772	2,725
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	5 years
Total intangible assets, gross carrying value	$ 1,410	1,410
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 6,340	1,840
Customer relationship | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	7 years
Customer relationship | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	10 years
License
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
Total intangible assets, gross carrying value	$ 6,200	$ 0

Composition of certain financ_7

Composition of certain financial statement captions - Schedule of future amortization expense (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Composition Of Certain Financial Statement [Abstract]
2023	$ 1,371
2024	1,358
2025	1,273
2026	1,242
2027-Thereafter	7,528
Net carrying value	$ 12,772	$ 2,725

Composition of certain financ_8

Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Goodwill [Roll Forward]
Goodwill balance at beginning of period	$ 8,307	$ 250
Goodwill acquired during the year		8,057
Goodwill adjustments during the year	25,314
Goodwill balance at end of period	$ 33,621	$ 8,307

Composition of certain financ_9

Composition of certain financial statement captions - Schedule of accounts receivable (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Composition Of Certain Financial Statement [Abstract]
Billed	$ 40,733	$ 28,464
Unbilled	392	1,287
Total accounts receivable, gross	41,125	29,751
Less accounts receivable allowances	(863)	(699)	$ (943)
Total accounts receivable	$ 40,262	$ 29,052

Composition of certain finan_10

Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Allowance for doubtful accounts at beginning of period	$ 699	$ 943
Bad debt expense	212	454
Write-offs and adjustments	(48)	(698)
Allowance for doubtful accounts at end of period	$ 863	$ 699

Composition of certain finan_11

Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Composition Of Certain Financial Statement [Abstract]
Prepaid software and business systems	$ 3,738	$ 2,322
Prepaid PhreesiaPads	0	18
Prepaid data center expenses	3,230	1,211
Prepaid insurance	1,924	1,311
Other prepaid expenses and other current assets	2,151	2,392
Total prepaid and other current assets	$ 11,043	$ 7,254

Revenue and Contract Costs - Na

Revenue and Contract Costs - Narrative (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Revenue from External Customer [Line Items]
Capitalized contract cost, amortization	$ 2,211,000	$ 2,025,000	$ 1,977,000
Capitalized contract cost, impairment loss	$ 0	0	0
Minimum
Revenue from External Customer [Line Items]
Capitalized contract cost, amortization period (in years)	3 years
Maximum
Revenue from External Customer [Line Items]
Capitalized contract cost, amortization period (in years)	5 years
Subscription and related services
Revenue from External Customer [Line Items]
Lease income	$ 6,489,000	$ 6,312,000	$ 5,985,000

Revenue and Contract Costs - Ro

Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Contract With Customer Asset [Roll Forward]
Beginning balance - Contract assets (unbilled accounts receivable)	$ 1,287	$ 676
Amount transferred to receivables from beginning balance of contract assets	(1,287)	(676)
Increases in contract assets due to acquisitions	243	0
Contract asset additions, net of reclassification to receivables	149	1,287
Ending balance - Contract assets (unbilled accounts receivable)	392	1,287
Contract With Customer Liability [Roll Forward]
Beginning balance - Contract liabilities (deferred revenue)	10,838	5,401
Revenue recognized that was included in deferred revenue at the beginning of the period	(10,838)	(5,097)
Revenue recognized that was not included in deferred revenue at the beginning of the period	(18,334)	(1,512)
Increases in deferred revenue due to acquisitions	2,372	55
Increases due to invoicing prior to satisfaction of performance obligations	32,520	11,991
Ending balance - Contract liabilities (deferred revenue)	$ 16,558	$ 10,838

Revenue and Contract Costs - Sc

Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Capitalized Contract Cost [Roll Forward]
Capitalized contract costs at beginning of period	$ 2,941	$ 3,314
Additions to deferred contract acquisition costs	3,349	1,652
Amortization of deferred contract acquisition costs	(2,211)	(2,025)	$ (1,977)
Capitalized contract costs at end of period	4,079	2,941	3,314
Deferred contract acquisition costs, current (to be amortized in next 12 months)	1,642	1,693
Deferred contract acquisition costs, non-current	2,437	1,248
Total deferred contract acquisition costs	$ 4,079	$ 2,941	$ 3,314

Finance leases and other debt -

Finance leases and other debt - Schedule Of Outstanding loan balances (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Debt Instrument [Line Items]
Finance leases	$ 12,884	$ 9,702
Long-term debt	360
Total finance lease liabilities and other debt	13,244	11,335
Less - current portion of finance lease liabilities and other debt	(5,821)	(4,864)
Long-term finance leases and other debt	7,423	6,471
Financing arrangements
Debt Instrument [Line Items]
Long-term debt	266	1,533
Accrued interest and payments
Debt Instrument [Line Items]
Long-term debt	$ 94	$ 100

Finance leases and other debt_2

Finance leases and other debt - Financing Agreements (Details) - USD ($) $ in Thousands	Apr. 10, 2020	Nov. 02, 2018	Jan. 31, 2022	Jan. 31, 2021	Jul. 21, 2020
Vendor Financing Agreement Maturing June 2022
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,256
Long term debt			$ 175	$ 504
Stated interest rate (as a percent)		9.83%
Installment payment, amount		$ 183
Vendor Financing Agreement Maturing May 2023
Debt Instrument [Line Items]
Debt instrument, face amount	$ 174
Long term debt			90	133
Stated interest rate (as a percent)	2.94%
Installment payment, amount	$ 46
Insurance Premium Financing Agreement
Debt Instrument [Line Items]
Long term debt			$ 0	$ 673
Stated interest rate (as a percent)					2.60%

Finance leases and other debt_3

Finance leases and other debt - Amended and Restated Loan and Security Agreement (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	May 05, 2020	Feb. 28, 2019
Debt Instrument [Line Items]
Debt extinguishment cost	$ 0	$ 0	$ (1,073,000)
Debt prepayment fee	$ 0	0	300,000
Term loan
Debt Instrument [Line Items]
Debt instrument, face amount					$ 20,000,000
Debt extinguishment cost			$ 1,073,000
Second SVB Facility
Debt Instrument [Line Items]
Interest rate (as a percent)	4.50%
Remaining borrowing capacity	$ 50,000,000
Second SVB Facility | Revolving credit facility
Debt Instrument [Line Items]
Line of credit borrowing capacity				$ 50,000,000
Accordion feature, potential new maximum borrowing capacity				65,000,000
Long term debt	$ 0	0		$ 20,663,000
Stated interest rate (as a percent)	4.50%
Scheduled reduction in interest rate (as a percent)	0.50%
Annual commitment fee	$ 125,000
Termination fee percentage (up to) (as a percent)				1.50%
Debt related fees incurred		$ 531,000
Debt prepayment fee	406,000
Line of credit entrance fee	$ 125,000

Finance leases and other debt_4

Finance leases and other debt - Schedule of Long-Term Debt Maturities (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Total
2023	$ 5,821
2024	4,866
2025	2,401
2026	156
2027	0
Total maturities of finance leases and other debt	13,244
Finance Leases
2023	5,600
2024	4,727
2025	2,401
2026	156
2027	0
Total finance lease liabilities	12,884	$ 9,702
Other Debt
2023	221
2024	139
2025	0
2026	0
2027	0
Total long-term debt maturities	$ 360

Finance leases and other debt_5

Finance leases and other debt - Schedule of Interest Income (Expense), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Debt Disclosure [Abstract]
Interest (expense) income, net	$ (1,163)	$ (1,695)	$ (3,043)
Interest income	79	122	598
Interest (expense) income, net	$ (1,084)	$ (1,573)	$ (2,445)

Stockholders' Equity and Pref_3

Stockholders' Equity and Preferred Stock - Additional Information (Details) - USD ($)	Apr. 12, 2021	Oct. 23, 2020	Jul. 22, 2019	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2019
Class of Stock [Line Items]
Common stock authorized (up to) (in shares)			500,000,000	500,000,000	500,000,000
Common stock par value			$ 0.01	$ 0.01	$ 0.01
Payment of offering costs				$ 0	$ 290,000	$ 6,217,000
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions				245,813,000	174,800,000	130,781,000
Issuance costs					290,000	6,412,000
Dividend paid				0	0	14,955,000
New issuances of preferred stock (in shares)				0	0
Balance of preferred stock				$ 0	$ 0	$ 0	$ 206,490,000
IPO
Class of Stock [Line Items]
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)			588,763
Dividend paid			$ 14,955,000
Follow-on Offering
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs (in shares)	5,175,000	5,750,000
Issue price per share (in dollars per share)	$ 50	$ 32
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions	$ 245,813,000	$ 174,800,000
Issuance costs		$ 290,000
Common stock
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs (in shares)				5,175,000	5,750,000	7,812,500
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)						25,311,535
Common stock | IPO
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs (in shares)			7,812,500
Issue price per share (in dollars per share)			$ 18
Proceeds from issuance of IPO, net of underwriters' discount and commissions			$ 130,781,000
Underwriting discounts and commission			9,844,000
Payment of offering costs			$ 6,412,000
Common stock | IPO | Certain selling stockholders
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs (in shares)			2,868,923

Stockholders' Equity and Pref_4

Stockholders' Equity and Preferred Stock - Schedule of Changes in Preferred Stock (Detail) $ in Thousands	12 Months Ended
	Jan. 31, 2020USD ($)shares
Stockholders’ equity
Beginning balance, redeemable preferred stock	$ 206,490
Accretion of redeemable preferred stock	56,175
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	(262,665)
Ending balance, redeemable preferred stock	$ 0
Senior A
Stockholders’ equity
Beginning balance, redeemable preferred stock (in shares) | shares	13,674,365
Beginning balance, redeemable preferred stock	$ 79,311
Accretion of redeemable preferred stock	$ 32,706
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares	(13,674,365)
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	$ (112,017)
Ending balance, redeemable preferred stock (in shares) | shares	0
Ending balance, redeemable preferred stock	$ 0
Senior B
Stockholders’ equity
Beginning balance, redeemable preferred stock (in shares) | shares	9,197,142
Beginning balance, redeemable preferred stock	$ 51,872
Accretion of redeemable preferred stock	$ 23,469
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares	(9,197,142)
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	$ (75,341)
Ending balance, redeemable preferred stock (in shares) | shares	0
Ending balance, redeemable preferred stock	$ 0
Junior
Stockholders’ equity
Beginning balance, redeemable preferred stock (in shares) | shares	32,746,041
Beginning balance, redeemable preferred stock	$ 32,746
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares	(32,746,041)
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	$ (32,746)
Ending balance, redeemable preferred stock (in shares) | shares	0
Ending balance, redeemable preferred stock	$ 0
Redeemable
Stockholders’ equity
Beginning balance, redeemable preferred stock (in shares) | shares	42,560,530
Beginning balance, redeemable preferred stock	$ 42,561
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares	(42,560,530)
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	$ (42,561)
Ending balance, redeemable preferred stock (in shares) | shares	0
Ending balance, redeemable preferred stock	$ 0

Equity-based compensation - Nar

Equity-based compensation - Narrative (Details) $ / shares in Units, $ in Thousands	Jan. 01, 2021	Dec. 31, 2020	Aug. 31, 2021	Jun. 30, 2019shares	Jan. 31, 2022USD ($)offering_period$ / sharesshares	Jan. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2020USD ($)$ / sharesshares	Jan. 31, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair market value of grants (in USD per share) | $ / shares					$ 46.60	$ 32.78	$ 21.31
Granted (in shares) | shares					0	0	1,230,382
Intrinsic value | $					$ 73,624	$ 33,575	$ 13,960
Unrecognized compensation cost to stock option | $					$ 1,415
Purchase of ESPP settlement (in shares) | shares					42,530
Issuance of common stock for employee stock purchase plan | $					$ 1,506
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares) | shares				855,873	737,800
ESPP, employee common stock purchase discount (as a percent)					15.00%
Unrecognized compensation costs | $					$ 830
Weighted average term for recognition (in years)					5 months
Employee purchase price of common stock (as a percent)					85.00%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)		7 years
Expiration period / maximum term (in years)		7 years
Unrecognized compensation costs | $					$ 102,442
Weighted average term for recognition (in years)					3 years 2 months 12 days
Bonus settlement in shares (as a percent)			115.00%
RSUs | Employees Other than NEOs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)	4 years
Quarterly vesting rate (as a percent)	6.25%
RSUs | NEOs and Other Members of Executive Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)	4 years
Quarterly vesting rate (as a percent)	6.25%
RSUs | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)		10.00%
Vesting term (in years)		1 year
RSUs | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)		20.00%
Vesting term (in years)		2 years
RSUs | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)		30.00%
Vesting term (in years)		3 years
RSUs | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)		40.00%
Vesting term (in years)		4 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					4 years
Expiration period / maximum term (in years)					10 years
Weighted average term for recognition (in years)					11 months 26 days
Weighted average fair market value of grants (in USD per share) | $ / shares							$ 4.99
Granted (in shares) | shares					0
Incremental expense associated with the modification of stock options | $					$ 363
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					100.00%
Vesting term (in years)					3 years
Unrecognized compensation costs | $					$ 19,265
Weighted average term for recognition (in years)					2 years 8 months 12 days
Weighted average fair market value of grants (in USD per share) | $ / shares					$ 48.47	$ 84.38
PSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					0.00%
PSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					200.00%
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares) | shares								3,048,490
2019 Stock Option And Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares) | shares				2,139,683
Percentage increase in number of shares reserved (as a percent)				5.00%
Number of shares available for grant (in shares) | shares					2,803,377
2019 Stock Option And Incentive Plan | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, number of offering periods per year | offering_period					2
ESPP offering period (in months)					6 months
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25.00%
Vesting term (in years)					1 year
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25.00%
Vesting term (in years)					1 year
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25.00%
Vesting term (in years)					1 year
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25.00%
Vesting term (in years)					1 year

Equity-based compensation - Sto

Equity-based compensation - Stock-based compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	$ 36,723	$ 13,489	$ 6,177
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	24,222	10,693	3,397
Liability awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	7,055	0	0
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	2,389	93	0
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	2,294	2,703	2,780
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	$ 763	$ 0	$ 0

Equity-based compensation - S_2

Equity-based compensation - Stock-based compensation in our financial statements (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 36,723	$ 13,489	$ 6,177
Less stock-based compensation expense capitalized as internal-use software	(489)	0	0
Stock-based compensation expense	36,234	13,489	6,177
Non-cash stock-based compensation expense	36,144	13,489	6,177
Cash settled stock based compensation expense	90
Additional paid-in capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	29,668	13,489	6,177
Accrued expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 7,055	$ 0	$ 0

Equity-based compensation - Val

Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details)	12 Months Ended
	Jan. 31, 2022$ / shares	Jan. 31, 2021$ / shares	Jan. 31, 2020$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair market value of grants (in USD per share)	$ 46.60	$ 32.78	$ 21.31
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Correlation coefficient	0.3878	0.4230
Valuation date stock price (in USD per share)	$ 36.03	$ 62.96
Simulation term (in years)	2 years 11 months 26 days	3 years
Volatility (as a percent)	44.32%	43.71%
Risk-free rate (as a percent)	1.23%	0.20%
Dividend yield (as a percent)	0.00%	0.00%
Weighted average fair market value of grants (in USD per share)	$ 48.47	$ 84.38

Equity-based compensation - Per

Equity-based compensation - Performance-based restricted stock units (Details) - shares	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
RSUs
Restricted Stock Unit Activity:
Beginning balance (in shares)	2,053,038	1,447,418	20,164
Granted (in shares)	1,836,534	972,271	1,493,678
Vested (in shares)	(559,767)	(242,049)	(43,011)
Forfeited and expired (in shares)	(195,966)	(124,602)	(23,413)
Ending balance (in shares)	3,133,839	2,053,038	1,447,418
PSUs
Restricted Stock Unit Activity:
Beginning balance (in shares)	70,806	0
Granted (in shares)	325,410	70,806
Vested (in shares)	0
Forfeited and expired (in shares)	0
Ending balance (in shares)	396,216	70,806	0

Equity-based compensation - Wei

Equity-based compensation - Weighted Average Assumptions (Details) - $ / shares	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of grants (in USD per share)	$ 46.60	$ 32.78	$ 21.31
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)			2.18%
Expected dividends (as a percent)			0.00%
Expected term (in years)			6 years 3 months
Volatility (as a percent)			45.15%
Weighted average fair value of grants (in USD per share)			$ 4.99
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)	0.17%
Expected dividends (as a percent)	0.00%
Expected term (in years)	5 months 26 days
Volatility (as a percent)	55.70%

Equity-based compensation - S_3

Equity-based compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Number of options
Number of options outstanding at beginning of period (in shares)	3,211,354	5,516,452	5,055,505
Granted (in shares)	0	0	1,230,382
Exercised (in shares)	(1,439,186)	(2,216,368)	(691,371)
Forfeited and expired (in shares)	(67,018)	(88,730)	(78,064)
Number of options outstanding at end of period (in shares)	1,705,150	3,211,354	5,516,452
Exercisable (in shares)	1,419,497
Amount vested at the end of the period (in shares)	551,341
Weighted- average exercise price
Weighted- average exercise price outstanding at beginning of period (in dollars per share)	$ 4.67	$ 3.80	$ 2.45
Granted (in dollars per share)	0	0	8.78
Exercised (in dollars per share)	2.88	2.39	2.62
Forfeited and expired (in dollars per share)	9.02	7.45	5.20
Weighted- average exercise price outstanding at end of period (in dollars per share)	6.01	$ 4.67	$ 3.80
Exercisable (in dollars per share)	5.46
Amount vested at the end of the period (in dollars per share)	$ 6.56
Weighted-average remaining contractual life of options outstanding and expected to vest (in years)	5 years 11 months 8 days	5 years 11 months 26 days	6 years 2 months 19 days
Weighted-average remaining contractual life of options exercisable (in years)	5 years 8 months 8 days
Aggregate intrinsic value outstanding and expected to vest	$ 42,938	$ 194,676	$ 150,152
Aggregate intrinsic value exercisable	$ 36,519

Fair value measurements - Sched

Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) - Fair value, recurring - USD ($)	Jan. 31, 2022	Jan. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	$ 197,601,000	$ 197,522,000
Foreign currency derivative contracts		148,000
Total assets	197,601,000	197,670,000
Acquisition related contingent consideration liabilities		(1,286,000)
Total liabilities		(1,286,000)
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	197,601,000	197,522,000
Foreign currency derivative contracts		0
Total assets	197,601,000	197,522,000
Acquisition related contingent consideration liabilities		0
Total liabilities		0
Significant Other Observable Inputs (Level 2)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Foreign currency derivative contracts	0	148,000
Total assets	0	148,000
Acquisition related contingent consideration liabilities		0
Total liabilities		0
Significant Unobservable Inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Foreign currency derivative contracts		0
Total assets	$ 0	0
Acquisition related contingent consideration liabilities		(1,286,000)
Total liabilities		$ (1,286,000)

Fair value measurements - Addit

Fair value measurements - Additional Information (Details) - Fair value, recurring - USD ($)	Jan. 31, 2022	Jan. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contracts		$ 148,000
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contracts	$ 0	$ 148,000

Fair value measurements - Sch_2

Fair value measurements - Schedule of Contingent Consideration Liabilities (Details) - QueueDr - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Jan. 31, 2022
Business Combination, Contingent Consideration Liability [Roll Forward]
Balance at January 31, 2021	$ 2,240	$ 1,286
Change in fair value recognized in earnings	71	258
Settlements	(1,025)	(1,544)
Balance at January 31, 2022	$ 1,286	$ 0

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term (in years)	2 years 2 months 12 days
Operating lease, weighted average discount rate (as a percent)	3.50%
Finance lease, weighted average remaining lease term (in years)	2 years 6 months
Finance lease, weighted average discount rate (as a percent)	3.70%
Subscription and related services
Lessee, Lease, Description [Line Items]
Lease income	$ 6,489	$ 6,312	$ 5,985
Computer equipment | Minimum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	2 years
Computer equipment | Maximum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	3 years

Leases - Schedule of operating

Leases - Schedule of operating and finance leases (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Leases [Abstract]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net of accumulated depreciation and amortization of $53,321 and $40,148 as of January 31, 2022 and 2021, respectively	Property and equipment, net of accumulated depreciation and amortization of $53,321 and $40,148 as of January 31, 2022 and 2021, respectively
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Long-term Debt and Lease Obligation, Current	Long-term Debt and Lease Obligation, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term finance leases and other debt	Long-term finance leases and other debt
Operating leases:
Lease right-of-use assets	$ 2,337	$ 2,654
Lease liabilities, current	1,281	1,087
Lease liabilities, non-current	1,276	1,899
Total operating lease liabilities	2,557	2,986
Finance leases:
Property and equipment, at cost	27,310	19,933
Accumulated depreciation	(15,025)	(10,389)
Property and equipment, net	12,285	9,544
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)	5,600	3,820
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)	7,284	5,882
Total finance lease liabilities	$ 12,884	$ 9,702

Leases - Schedule of lease expe

Leases - Schedule of lease expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Operating leases:
Operating lease cost	$ 1,096	$ 1,766
Variable lease cost	223	257
Total operating lease cost	1,319	2,023
Finance leases:
Amortization of right-of-use assets	4,636	2,876
Interest on lease liabilities	378	326
Total finance lease cost	$ 5,014	$ 3,202

Leases - Schedule of maturing l

Leases - Schedule of maturing lease payments (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Operating
2023	$ 1,348
2024	960
2025	225
2026	86
2027	42
Total future minimum lease payments	2,661
Less: interest	(104)
Total operating lease liabilities	2,557	$ 2,986
Finance
2023	5,956
2024	4,894
2025	2,444
2026	158
2027	0
Total future minimum lease payments	13,452
Less: interest	(568)
Finance leases	$ 12,884	$ 9,702

Leases - Schedule of supplement

Leases - Schedule of supplemental cash flow information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases	$ 1,206	$ 1,629
Operating cash used for finance leases	377	326
Financing cash used for finance leases	4,267	2,630	$ 1,898
Total cash paid in measurement of lease liabilities	$ 5,850	$ 4,585

Commitments and contingencies (

Commitments and contingencies (Details) - QueueDr - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Jan. 31, 2022	Jan. 08, 2021
Loss Contingencies [Line Items]
Contingent consideration, liability	$ 1,286	$ 0	$ 2,240
Settlement of liability	$ 1,025	$ 1,544

Commitments and contingencies -

Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details) $ in Thousands	Jan. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 6,638
2024	7,200
2025	3,261
2026	810
Thereafter	150
Total	$ 18,059

Income taxes - Narratives (Deta

Income taxes - Narratives (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Operating Loss Carryforwards [Line Items]
(Provision for) benefit from income taxes	$ (182,000)	$ (49,000)	$ 1,780,000
Effective tax rate (as a percent)	0.20%	0.20%	8.10%
Valuation allowance	$ (97,279,000)	$ (54,563,000)
Increase in valuation allowance	42,716,000
Tax examination, penalties and interest accrued	0
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Accumulated federal net operating loss carryforward	332,544,000	$ 199,079,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Accumulated federal net operating loss carryforward	$ 1,943,000

Income taxes - Components of ta

Income taxes - Components of tax (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Current tax
Federal	$ 0	$ 0	$ 0
State	39	114	0
Foreign	0	0	(1,005)
Deferred tax
Federal	0	(116)	0
State	0	(65)	0
Foreign	143	116	(775)
Total provision for (benefit from) income taxes	$ 182	$ 49	$ (1,780)

Income taxes - Effective tax ra

Income taxes - Effective tax rate reconciliation (Details)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate (as a percent)	21.00%	21.00%	21.00%
State and local tax, net of federal benefit (as a percent)	9.00%	10.00%	3.00%
Permanent differences (as a percent)	0.00%	0.00%	(2.00%)
Equity compensation (as a percent)	6.00%	44.00%	7.00%
Foreign taxes (as a percent)	0.00%	0.00%	8.00%
Other (as a percent)	0.00%	(4.00%)	(4.00%)
Change in valuation allowance (as a percent)	(36.00%)	(71.00%)	(25.00%)
Effective income tax rate (as a percent)	0.20%	0.20%	8.10%

Income taxes - Company's Deferr

Income taxes - Company's Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Deferred tax assets
Net operating loss carryforwards	$ 88,979	$ 51,973
Stock based compensation	5,374	1,162
Accruals, reserves, and other expenses	3,697	2,823
Reserve for bad debts	521	443
Disallowed interest expense	1,934	1,586
Total deferred tax assets	100,505	57,987
Less valuation allowance	(97,279)	(54,563)
Net deferred tax assets	3,226	3,424
Depreciation and amortization	(1,250)	(1,568)
Intangible assets	(373)	(440)
Deferred contract acquisition costs	(1,088)	(758)
Total deferred tax liabilities	(2,711)	(2,766)
Deferred taxes, net	$ 515	$ 658

Income taxes - Unrecognized tax

Income taxes - Unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized income tax benefits, opening balance	$ 0	$ 0	$ 1,000
Increase for income tax positions of prior years	0	0	0
Lapse of statute of limitations	0	0	(1,000)
Unrecognized income tax benefits, ending balance	$ 0	$ 0	$ 0

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Schedule of computation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Numerator:
Net loss	$ (118,161)	$ (27,292)	$ (20,293)
Preferred stock dividend paid	0	0	(14,955)
Accretion of redeemable convertible preferred stock to redemption value	0	0	(56,175)
Net loss attributable to common stockholders	$ (118,161)	$ (27,292)	$ (91,423)
Denominator:
Weighted-average common shares outstanding - basic (in shares)	49,888,436	39,519,640	20,301,189
Weighted-average common shares outstanding - diluted (in shares)	49,888,436	39,519,640	20,301,189
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (2.37)	$ (0.69)	$ (4.50)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (2.37)	$ (0.69)	$ (4.50)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) - shares	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,708,193	5,406,004	7,039,007
Stock options to purchase common stock, restricted stock units and performance stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,632,823	5,406,004	6,963,870
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	75,370	0	0
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	75,137

Retirement savings plan (Detail

Retirement savings plan (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Retirement Benefits [Abstract]
Company contributions	$ 0	$ 0	$ 0

Related party transactions (Det

Related party transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Advertisements with Pharmaceutical Company | Affiliate of Director
Related Party Transaction [Line Items]
Recognized revenue from related parties	$ 482
Accounts receivable from related parties	173	$ 68
Software Agreement | Affiliate of Director
Related Party Transaction [Line Items]
Expenses from transactions with related parties	412
General and administrative expenses from transactions with related party	182
Software Agreement | Affiliate of Director | Prepaid and other current assets
Related Party Transaction [Line Items]
Due from related parties, current	374
Software Agreement | Affiliate of Director | Other assets
Related Party Transaction [Line Items]
Due from related parties, concurrent	$ 51
Revenue from Affiliate of Stockholder | Affiliated Entity
Related Party Transaction [Line Items]
Recognized revenue from related parties		$ 2,425	$ 5,318
Accounts receivable from related parties			$ 2,072

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands	Dec. 03, 2021	Jan. 08, 2021	Jan. 31, 2022	Jan. 31, 2021
Insignia
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)	100.00%
Consideration transferred	$ 37,208
Weighted average amortization period (in years)		13 years
Acquisition related costs			$ 720
Cash consideration paid on acquisition date	37,112
Liabilities incurred	$ 96
QueueDr
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)		100.00%
Consideration transferred		$ 10,124
Weighted average amortization period (in years)		7 years 4 months 24 days
Acquisition related costs				$ 282
Cash consideration paid on acquisition date		$ 5,773
Liabilities incurred		2,111
Contingent consideration		2,240
QueueDr | Maximum
Business Acquisition [Line Items]
Contingent consideration liability		$ 2,574

Acquisitions - Schedule of Insi

Acquisitions - Schedule of Insignia Health, LLC and QueueDr Purchase Price Consideration (Details) - USD ($) $ in Thousands	Dec. 03, 2021	Jan. 08, 2021
Insignia
Business Acquisition [Line Items]
Cash consideration paid on acquisition date	$ 37,112
Liabilities incurred	96
Total fair value of acquisition consideration	$ 37,208
QueueDr
Business Acquisition [Line Items]
Cash consideration paid on acquisition date		$ 5,773
Liabilities incurred		2,111
Contingent consideration		2,240
Total fair value of acquisition consideration		$ 10,124

Acquisitions - Schedule of Cons

Acquisitions - Schedule of Consideration Paid (Details) - USD ($) $ in Thousands	Dec. 03, 2021	Jan. 08, 2021	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Business Acquisition [Line Items]
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows			$ 34,423	$ 6,510	$ 0
Insignia
Business Acquisition [Line Items]
Cash consideration paid on acquisition date	$ 37,112
Less cash acquired	(2,689)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows	$ 34,423
QueueDr
Business Acquisition [Line Items]
Cash consideration paid on acquisition date		$ 5,773
Payments of acquisition date fair value of contingent consideration		954
Less cash acquired		(217)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows		$ 6,510

Acquisitions - Schedule of Fina

Acquisitions - Schedule of Final Allocation of Insignia Health, LLCand QueueDr Purchase Price (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Dec. 03, 2021	Jan. 31, 2021	Jan. 08, 2021	Jan. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 33,621		$ 8,307		$ 250
Insignia
Business Acquisition [Line Items]
Cash		$ 2,689
Accounts receivable		994
Prepaid expenses and other assets		358
Operating lease right-of-use assets		606
Intangibles		10,700
Identified intangible assets acquired		10,700
Goodwill		25,410
Total assets acquired		40,757
Accounts payable		(84)
Accrued liabilities		(487)
Deferred revenue		(2,372)
Operating lease liabilities		(606)
Total purchase price		$ 37,208
QueueDr
Business Acquisition [Line Items]
Cash				$ 217
Accounts receivable				455
Other current assets				192
Identified intangible assets acquired				1,780
Deferred tax asset				262
Goodwill				8,057
Other assets				223
Total assets acquired				11,186
Accounts payable				(86)
Accrued liabilities				(254)
Deferred revenue				(55)
Long-term debt				(223)
Deferred tax liability				(444)
Total purchase price				$ 10,124

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Asset Acquired Related to Insignia Health, LLC and QueueDr Acquisition (Details) - USD ($) $ in Thousands	Dec. 03, 2021	Jan. 08, 2021	Jan. 31, 2022
License
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)			15 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)			5 years
Insignia
Acquired Finite-Lived Intangible Assets [Line Items]
Total identifiable intangible assets acquired	$ 10,700
Insignia | License
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	15 years
Total identifiable intangible assets acquired	$ 6,200
Insignia | Customer relationship
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	10 years
Total identifiable intangible assets acquired	$ 4,500
QueueDr
Acquired Finite-Lived Intangible Assets [Line Items]
Total identifiable intangible assets acquired		$ 1,780
QueueDr | Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		5 years
Total identifiable intangible assets acquired		$ 920
QueueDr | Customer relationship
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		10 years
Total identifiable intangible assets acquired		$ 860

Subsequent events (Details)

Subsequent events (Details) - Subsequent event - Third SVB Facility - Revolving credit facility $ in Millions	Mar. 28, 2022USD ($)
Subsequent Event [Line Items]
Line of credit borrowing capacity	$ 100
Stated interest rate (as a percent)	3.25%
Annual commitment fee	$ 0.3
Unused capacity, commitment fee (as a percent)	0.15%
Wall Street Journal Prime Rate
Subsequent Event [Line Items]
Variable rate (as a percent)	(0.50%)